

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS AND
INDEPENDENT AUDITORS' REPORT
DECEMBER 31, 2025 AND 2024

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
DECEMBER 31, 2025 AND 2024 CONSOLIDATED FINANCIAL STATEMENTS
AND INDEPENDENT AUDITORS' REPORT
TABLE OF CONTENTS

Contents	Page
1. Cover Page	1
2. Table of Contents	2 ~ 3
3. Declaration of Consolidated Financial Statements of Affiliated Enterprises	4
4. Independent Auditors' Report	5 ~ 11
5. Consolidated Balance Sheets	12 ~ 13
6. Consolidated Statements of Comprehensive Income	14
7. Consolidated Statements of Changes in Equity	15
8. Consolidated Statements of Cash Flows	16 ~ 17
9. Notes to the Consolidated Financial Statements	18 ~ 70
(1) HISTORY AND ORGANISATION	18
(2) THE DATE OF AUTHORISATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORISATION	18
(3) APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS	18 ~ 19
(4) SUMMARY OF MATERIAL ACCOUNTING POLICIES	20 ~ 31

Contents	Page
(5) CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY	31 ~ 32
(6) DETAILS OF SIGNIFICANT ACCOUNTS	32 ~ 56
(7) RELATED PARTY TRANSACTIONS	57 ~ 58
(8) PLEDGED ASSETS	58
(9) SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT COMMITMENTS	58
(10) SIGNIFICANT DISASTER LOSS	58
(11) SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE	58
(12) OTHERS	58 ~ 66
(13) SUPPLEMENTARY DISCLOSURES	66
A. Significant transactions information	66
B. Information on investees	66
C. Information on investments in Mainland China	66
(14) SEGMENT INFORMATION	66 ~ 70

SCINOPHARM TAIWAN, LTD.

Declaration of Consolidated Financial Statements of Affiliated Enterprises

For the year ended December 31, 2025, pursuant to “Criteria Governing Preparation of Affiliation Reports, Consolidated Business Reports and Consolidated Financial Statements of Affiliated Enterprises,” the entities that are required to be included in the consolidated financial statements of affiliates, are the same as the entities required to be included in the consolidated financial statements under International Financial Reporting Standards 10. In addition, information required to be disclosed in the consolidated financial statements of affiliates is included in the aforementioned consolidated financial statements. Accordingly, it is not required to prepare a separate set of consolidated financial statements of affiliates.

Hereby declare,

SCINOPHARM TAIWAN, LTD.

By Alex Lo

Chairman

March 4, 2026

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of ScinoPharm Taiwan, Ltd.

Opinion

We have audited the accompanying consolidated balance sheets of ScinoPharm Taiwan, Ltd. and subsidiaries (the "Group") as at December 31, 2025 and 2024, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of material accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at December 31, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial Supervisory Commission.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the *Auditors' responsibilities for the audit of the consolidated financial statements* section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Accountants of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Group's 2025 consolidated financial statements. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

The key audit matters for the Group's 2025 consolidated financial statements are stated as follows:

Occurrence of sales revenues from API and injection products

Description

Refer to Note 4(27) for accounting policy on revenue recognition and Note 6(17) for accounting items on revenue.

The Group's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient ("API") and injection products. The Group's customers come from Taiwan, Asia, Europe and America. Since the volume and amount of transactions are significant, we considered the occurrence of sales revenue from API and injection products a key audit matter.

How our audit addressed the matter

We performed the following key audit procedures in response to the above key audit matter:

1. We evaluated the internal control system that was designed and implemented by management in reviewing customers' credit, and tested whether the counterparty and the credit valuation documents have been properly approved.
2. We sampled transaction details and supporting documents for consistency from transaction counterparties who have higher turnover growth.
3. We sent confirmation letters for significant year-end accounts receivable, ascertained whether the responses and account records were consistent with customers' data, and evaluated the reasonableness on the difference between the responses and the account records.

Inventory valuation

Description

Refer to Note 4(12) for accounting policies on inventory valuation, Note 5(2) for the uncertainty of accounting estimates and assumptions applied in inventory valuation, and Note 6(4) for details of inventories. As at December 31, 2025, the balances of inventory and allowance for inventory valuation losses were \$2,117,946 thousand and \$481,406 thousand, respectively.

The Group is primarily engaged in the manufacture and sales of API. Due to the complex manufacturing process, long lead time in materials preparation and uncertain product registration timing before market launch, there is a higher risk of incurring loss on inventory valuation. For inventories sold under normal terms, the Group measures inventories at the lower of cost and net realisable value. For inventories ageing over a certain period of time or are individually identified as obsolete inventories, the net realisable value is calculated based on the historical information of inventory turnover. Since the calculation of net realisable value involves subjective judgement and the ending balance of inventory is material to the financial statements, we considered the valuation of inventory a key audit matter.

How our audit addressed the matter

We performed the following key audit procedures in response to the above key audit matter:

1. We compared the financial statements to ascertain whether the provision policy on allowance for inventory valuation losses has been consistently applied and assessed the reasonableness of the provision policy.
2. We understood the inventory management process, observing annual physical counts to assess the effectiveness of management's classification and controls over obsolete and slow-moving inventory.

3. We sampled and verified the accuracy of inventory ageing report and evaluated whether the older inventories were obsolete.
4. We sampled the computation of net realisable value of individual inventory and compared with account records.

Other matter – Parent company only financial reports

We have audited and expressed an unmodified opinion on the parent company only financial statements of ScinoPharm Taiwan, Ltd. as at and for the years ended December 31, 2025 and 2024.

Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial Supervisory Commission, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee, are responsible for overseeing the Group's financial reporting process.

Auditors' responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in

our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Yeh, Fang-Ting

Independent Accountants

Hsu, Hui-Yu

PricewaterhouseCoopers, Taiwan

Republic of China

March 4, 2026

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

Assets	Notes	December 31, 2025		December 31, 2024		
		AMOUNT	%	AMOUNT	%	
Current assets						
1100	Cash and cash equivalents	6(1)	\$ 3,110,074	26	\$ 4,165,987	35
1110	Financial assets at fair value through profit or loss - current	6(2)	90	-	-	-
1140	Contract assets - current	6(17)	-	-	29,397	-
1170	Accounts receivable, net	6(3) and 12	612,411	5	604,219	5
1200	Other receivables		11,616	-	20,572	-
130X	Inventories	5 and 6(4)	1,636,540	14	1,673,007	14
1410	Prepayments		119,990	1	114,908	1
11XX	Total current assets		<u>5,490,721</u>	<u>46</u>	<u>6,608,090</u>	<u>55</u>
Non-current assets						
1517	Financial assets at fair value through other comprehensive income - non- current	6(5)	1,367,738	12	70,134	1
1600	Property, plant and equipment	6(6)(8) and 7	3,408,782	29	3,738,889	32
1755	Right-of-use assets	6(7)	674,278	6	686,635	6
1780	Intangible assets	6(6)	15,363	-	17,130	-
1840	Deferred income tax assets	5 and 6(24)	664,626	6	625,260	5
1915	Prepayments for equipment	6(6)	144,633	1	150,890	1
1920	Guarantee deposits paid		3,022	-	2,367	-
1980	Other financial assets - non-current	6(1) and 8	29,270	-	30,940	-
1990	Other non-current assets	6(6)	59,292	-	12,403	-
15XX	Total non-current assets		<u>6,367,004</u>	<u>54</u>	<u>5,334,648</u>	<u>45</u>
1XXX	Total assets		<u>\$ 11,857,725</u>	<u>100</u>	<u>\$ 11,942,738</u>	<u>100</u>

(Continued)

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

Liabilities and Equity	Notes	December 31, 2025		December 31, 2024		
		AMOUNT	%	AMOUNT	%	
Current liabilities						
2100	Short-term borrowings	6(9)	\$ 130,424	1	\$ 35,563	-
2120	Financial liabilities at fair value through profit or loss - current	6(2)	-	-	1,225	-
2130	Contract liabilities - current	6(17)	115,351	1	119,396	1
2150	Notes payable		12	-	1,211	-
2170	Accounts payable		62,515	1	80,959	1
2200	Other payables	6(10)	363,581	3	498,191	4
2230	Current income tax liabilities	6(24)	14,499	-	11,499	-
2280	Lease liabilities - current		23,461	-	19,638	-
21XX	Total current liabilities		<u>709,843</u>	<u>6</u>	<u>767,682</u>	<u>6</u>
Non-current liabilities						
2570	Deferred income tax liabilities	6(24)	628	-	1,304	-
2580	Lease liabilities - non-current		608,777	5	620,342	5
2640	Net defined benefit liabilities - non-current	6(11)	10,694	-	23,614	1
2645	Guarantee deposits received		3,046	-	3,992	-
25XX	Total non-current liabilities		<u>623,145</u>	<u>5</u>	<u>649,252</u>	<u>6</u>
2XXX	Total liabilities		<u>1,332,988</u>	<u>11</u>	<u>1,416,934</u>	<u>12</u>
Equity attributable to owners of parent						
	Share capital	6(12)				
3110	Common stock		7,907,392	67	7,907,392	66
3200	Capital surplus	6(13)	1,294,689	11	1,294,689	10
	Retained earnings	6(15)				
3310	Legal reserve		817,709	7	783,817	7
3320	Special reserve		126,177	1	185,856	2
3350	Unappropriated earnings		366,455	3	480,227	4
3400	Other equity interest	6(16)	12,315	-	(126,177)	(1)
3XXX	Total equity		<u>10,524,737</u>	<u>89</u>	<u>10,525,804</u>	<u>88</u>
	Significant contingent liabilities and unrecognised contract commitments	9				
3X2X	Total liabilities and equity		<u>\$ 11,857,725</u>	<u>100</u>	<u>\$ 11,942,738</u>	<u>100</u>

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars, except for earnings per share amount)

Items	Notes	Year ended December 31				
		2025		2024		
		AMOUNT	%	AMOUNT	%	
4000	Operating revenue	6(17)	\$ 3,163,422	100	\$ 3,406,284	100
5000	Operating costs	6(4)(11)(22)(23)	(2,066,983)	(66)	(2,106,074)	(62)
5900	Net operating margin		1,096,439	34	1,300,210	38
	Operating expenses	6(7)(11)(22)(23), 7 and 12				
6100	Selling expenses		(127,049)	(4)	(141,723)	(4)
6200	General and administrative expenses		(363,248)	(11)	(376,420)	(11)
6300	Research and development expenses		(497,277)	(16)	(459,358)	(14)
6450	Expected credit gain (loss)		41	-	(1,668)	-
6000	Total operating expenses		(987,533)	(31)	(979,169)	(29)
6900	Operating profit		108,906	3	321,041	9
	Non-operating income and expenses					
7100	Interest income	6(18)	53,376	1	61,521	2
7010	Other income	6(5)(19)	30,444	1	29,894	1
7020	Other gains and losses	6(2)(8)(20) and 12	(35,484)	(1)	8,644	-
7050	Finance costs	6(7)(21)	(9,867)	-	(8,083)	-
7000	Total non-operating income and expenses		38,469	1	91,976	3
7900	Profit before income tax		147,375	4	413,017	12
7950	Income tax expense	6(24)	(10,424)	-	(73,667)	(2)
8200	Profit for the year		\$ 136,951	4	\$ 339,350	10
	Other comprehensive income (loss)					
	Components of other comprehensive income (loss) that will not be reclassified to profit or loss					
8311	Actuarial gains (losses) on defined benefit plans	6(11)	\$ 311	-	(\$ 540)	-
8316	Unrealised gain from equity instruments measured at fair value through other comprehensive income	6(5)(16)	141,604	5	161	-
8349	Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	6(24)	(62)	-	107	-
	Components of other comprehensive income (loss) that will be reclassified to profit or loss					
8361	Financial statements translation differences of foreign operations	6(16)	(3,112)	-	59,518	2
8300	Total other comprehensive income for the year		\$ 138,741	5	\$ 59,246	2
8500	Total comprehensive income for the year		\$ 275,692	9	\$ 398,596	12
	Profit attributable to:					
8610	Owners of the parent		\$ 136,951	4	\$ 339,350	10
	Comprehensive income attributable to:					
8710	Owners of the parent		\$ 275,692	9	\$ 398,596	12
	Earnings per share (in dollars)	6(25)				
9750	Basic		\$ 0.17		\$ 0.43	
9850	Diluted		\$ 0.17		\$ 0.43	

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
YEARS ENDED DECEMBER 31, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

	Notes	Equity attributable to owners of the parent						Other Equity Interest	Total equity
		Share capital - common stock	Capital reserve	Legal reserve	Special reserve	Unappropriated earnings	Financial statements translation differences of foreign operations		
Year ended December 31, 2024									
Balance at January 1, 2024		\$ 7,907,392	\$ 1,294,689	\$ 755,145	\$ 98,176	\$ 494,884	(\$ 88,156)	(\$ 97,700)	\$ 10,364,430
Net income for the year		-	-	-	-	339,350	-	-	339,350
Other comprehensive income (loss) for the year	6(5)(16)	-	-	-	-	(433)	59,518	161	59,246
Total comprehensive income for the year		-	-	-	-	338,917	59,518	161	398,596
Distribution of 2023 net income:									
Legal reserve		-	-	28,672	-	(28,672)	-	-	-
Special reserve		-	-	-	87,680	(87,680)	-	-	-
Cash dividends	6(15)	-	-	-	-	(237,222)	-	-	(237,222)
Balance at December 31, 2024		\$ 7,907,392	\$ 1,294,689	\$ 783,817	\$ 185,856	\$ 480,227	(\$ 28,638)	(\$ 97,539)	\$ 10,525,804
Year ended December 31, 2025									
Balance at January 1, 2025		\$ 7,907,392	\$ 1,294,689	\$ 783,817	\$ 185,856	\$ 480,227	(\$ 28,638)	(\$ 97,539)	\$ 10,525,804
Net income for the year		-	-	-	-	136,951	-	-	136,951
Other comprehensive income (loss) for the year	6(5)(16)	-	-	-	-	249	(3,112)	141,604	138,741
Total comprehensive income (loss) for the year		-	-	-	-	137,200	(3,112)	141,604	275,692
Distribution of 2024 net income:									
Legal reserve		-	-	33,892	-	(33,892)	-	-	-
Cash dividends	6(15)	-	-	-	-	(276,759)	-	-	(276,759)
Reversal of special reserve		-	-	-	(59,679)	59,679	-	-	-
Balance at December 31, 2025		\$ 7,907,392	\$ 1,294,689	\$ 817,709	\$ 126,177	\$ 366,455	(\$ 31,750)	\$ 44,065	\$ 10,524,737

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

	Notes	Year ended December 31	
		2025	2024
<u>CASH FLOWS FROM OPERATING ACTIVITIES</u>			
Profit before tax		\$ 147,375	\$ 413,017
Adjustments			
Adjustments to reconcile profit (loss)			
(Gain) loss on valuation of financial assets and liabilities at fair value through profit or loss		(1,315)	9,529
Expected credit (gain) loss	12	(41)	1,668
Loss on inventory market price decline	6(4)	65,207	9,978
Depreciation of property, plant and equipment	6(6)(22)	475,671	461,545
Depreciation of right-of-use assets	6(7)(22)	20,620	17,241
Property, plant and equipment transferred to loss	6(6)	-	119
(Gain on reversal of) impairment loss	6(6)(8)(20)	(2,251)	1,119
Loss on disposal of property, plant and equipment	6(20)	185	4,636
Amortisation	6(22)	20,437	9,495
Interest income	6(18)	(53,376)	(61,521)
Dividend income	6(5)(19)	(25,615)	-
Interest expense	6(21)	9,867	8,083
Changes in operating assets and liabilities			
Changes in operating assets			
Contract assets - current		29,397	(29,397)
Accounts receivable		(8,151)	182,329
Other receivables		7,045	5,358
Inventories		(32,608)	(175,181)
Prepayments		(1,274)	(7,936)
Changes in operating liabilities			
Contract liabilities - current		(4,045)	8,429
Notes payable		(1,199)	32
Accounts payable		(18,444)	(20,319)
Other payables		(42,693)	(3,025)
Net defined benefit liabilities - non-current		(12,609)	(31,440)
Cash inflow generated from operations		572,183	803,759
Interest received		55,287	60,821
Dividends received		25,615	-
Interest paid		(9,788)	(8,069)
Income tax paid		(47,389)	(105,598)
Net cash flows from operating activities		<u>595,908</u>	<u>750,913</u>

(Continued)

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2025 AND 2024
(Expressed in thousands of New Taiwan dollars)

	Notes	Year ended December 31	
		2025	2024
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Acquisition of financial assets at fair value through other comprehensive income - non-current		(\$ 1,156,000)	\$ -
Cash paid for acquisition of property, plant and equipment	6(26)	(145,375)	(114,877)
Proceeds from disposal of property, plant and equipment		1,463	6,218
Acquisition of intangible assets		(4,948)	(8,563)
Cash paid for prepayments for equipment	6(26)	(145,914)	(165,292)
(Increase) decrease in guarantee deposits paid		(655)	86
Decrease in other financial assets - non-current		1,670	-
Increase in other non-current assets		(1,737)	(10,955)
Net cash flows used in investing activities		(1,451,496)	(293,383)
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Increase in short-term borrowings	6(27)	141,372	35,326
Decrease in short-term borrowings	6(27)	(50,039)	(33,156)
Repayment of the principal portion of lease liabilities	6(27)	(15,983)	(12,472)
(Decrease) increase in guarantee deposits received	6(27)	(890)	2,637
Payment of cash dividends	6(15)	(276,759)	(237,222)
Net cash flows used in financing activities		(202,299)	(244,887)
Effect of foreign exchange rate changes		1,974	11,820
Net (decrease) increase in cash and cash equivalents		(1,055,913)	224,463
Cash and cash equivalents at beginning of year	6(1)	4,165,987	3,941,524
Cash and cash equivalents at end of year	6(1)	\$ 3,110,074	\$ 4,165,987

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

1. HISTORY AND ORGANISATION

- (1) ScinoPharm Taiwan, Ltd. (the “Company”) was incorporated as a company limited by shares under the provisions of the Company Act of the Republic of China (R.O.C.) on November 11, 1997. The Company and its subsidiaries (the “Group”) are primarily engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade and research, development, production, manufacture and sales of Active Pharmaceutical Ingredients (“API”), albumin medicines, oligonucleotide medicines, peptide medicines, injections and new small molecule drugs, as well as the provision of related consulting and technical services and international trade for the above products. In addition, the Company sells the chemical material which is reprocessed from the material recycled from the Company’s manufacturing process. For more information regarding the manufacturing and trading activities the Group are engaged in, refer to Note 4(3), “Basis of consolidation”.
- (2) The common shares of the Company have been listed on the Taiwan Stock Exchange since September 2011.
- (3) Uni-President Enterprises Corp., the Company’s ultimate parent company, holds 37.94% equity interest in the Company.

2. THE DATE OF AUTHORISATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORISATION

These consolidated financial statements were authorised for issuance by the Board of Directors on March 4, 2026.

3. APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS

- (1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS®”) Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission (“FSC”)

New standards, interpretations and amendments endorsed by the FSC and became effective from 2025 are as follows:

<u>New Standards, Interpretations and Amendments</u>	<u>Effective date by International Accounting Standards Board (“IASB”)</u>
Amendments to IAS 21, ‘Lack of Exchangeability’	January 1, 2025

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but not yet adopted by the Group

New standards, interpretations and amendments endorsed by the FSC effective from 2026 are as follows:

New Standards, Interpretations and Amendments	Effective date by IASB
Amendments to IFRS 9 and IFRS 7, ‘Amendments to the classification and measurement of financial instruments’	January 1, 2026
Amendments to IFRS 9 and IFRS 7, ‘Contracts referencing nature-dependent electricity’	January 1, 2026
IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendments to IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendment to IFRS 17, ‘Initial application of IFRS 17 and IFRS 9 – comparative information’	January 1, 2023
Annual Improvements to IFRS Accounting Standards – Volume 11	January 1, 2026

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(3) IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRS Accounting Standards as endorsed by the FSC are as follows:

New Standards, Interpretations and Amendments	Effective date by IASB
Amendments to IFRS 10 and IAS 28, ‘Sale or contribution of assets between an investor and its associate or joint venture’	To be determined by IASB
IFRS 18, ‘Presentation and disclosure in financial statements’	January 1, 2027 (Note)
IFRS 19, ‘Subsidiaries without public accountability: disclosures’	January 1, 2027
Amendments to IAS 21, ‘Translation to a Hyperinflationary Presentation Currency’	January 1, 2027

Note : The FSC has announced in a press release on September 25, 2025 that public companies will apply IFRS 18 starting from the fiscal year 2028. Additionally, entities can choose to adopt IFRS 18 earlier based on their requirements after the FSC endorses IFRS 18.

Except for the following, the above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

IFRS 18, ‘Presentation and disclosure in financial statements’

IFRS 18, ‘Presentation and disclosure in financial statements’ replaces IAS 1. The standard introduces a defined structure of the statement of profit or loss, disclosure requirements related to management-defined performance measures, and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes.

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

(1) Compliance statement

The consolidated financial statements of the Group have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, International Financial Reporting Standards, International Accounting Standards, IFRIC[®] Interpretations, and SIC[®] Interpretations that came into effect as endorsed by the FSC (collectively referred herein as the “IFRSs”).

(2) Basis of preparation

A. Except for the following items, these consolidated financial statements have been prepared under the historical cost convention:

- (a) Financial assets and financial liabilities (including derivative instruments) at fair value through profit or loss.
- (b) Financial assets at fair value through other comprehensive income.
- (c) Defined benefit liabilities recognised based on the net amount of pension fund assets less present value of defined benefit obligation.

B. The preparation of financial statements in conformity with IFRSs requires that use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.

(3) Basis of consolidation

A. Basis for preparation of consolidated financial statements:

- (a) All subsidiaries are included in the Group’s consolidated financial statements. Subsidiaries are all entities (including structured entities) controlled by the Group. The Group controls an entity when the Group is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Consolidation of subsidiaries begins from the date the Group obtains control of the subsidiaries and ceases when the Group loses control of the subsidiaries.
- (b) Inter-company transactions, balances and unrealised gains or losses on transactions between companies within the Group are eliminated. Accounting policies of subsidiaries have been adjusted where necessary to ensure consistency with the policies adopted by the Group.
- (c) Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests. Total comprehensive income is attributed to the owners of the parent and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

- (d) Changes in a parent's ownership interest in a subsidiary that do not result in the parent losing control of the subsidiary (transactions with non-controlling interests) are accounted for as equity transactions, i.e. transactions with owners in their capacity as owners. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognised directly in equity.
- (e) When the Group loses control of a subsidiary, the Group remeasures any investment retained in the former subsidiary at its fair value. That fair value is regarded as the fair value on initial recognition of a financial asset or the cost on initial recognition of the associate or joint venture. Any difference between fair value and carrying amount is recognised in profit or loss. All amounts previously recognised in other comprehensive income in relation to the subsidiary are reclassified to profit or loss on the same basis as would be required if the related assets or liabilities were disposed of. That is, when the Group loses control of a subsidiary, all gains or losses previously recognised in other comprehensive income in relation to the subsidiary should be reclassified from equity to profit or loss, if such gains or losses would be reclassified to profit or loss when the related assets or liabilities are disposed of.

B. Subsidiaries included in the consolidated financial statements:

Name of Investors	Name of Subsidiaries	Business Activities	Percentage owned by the Company		Note
			December 31, 2025	December 31, 2024	
ScinoPharm Taiwan, Ltd.	SPT International, Ltd.	Professional investment	100.00	100.00	—
	ScinoPharm Singapore Pte Ltd.	Professional investment	100.00	100.00	—
SPT International, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	Research, development and manufacture of API and new drugs, sales of self-produced products, etc.	100.00	100.00	—
	SciAnda Shanghai Biochemical Technology, Ltd.	Import, export and sales of API and intermediates, etc.	100.00	100.00	—

C. Subsidiaries not included in the consolidated financial statements: None.

D. Adjustments for subsidiaries with different balance sheet dates: None.

E. Significant restrictions: None.

F. Subsidiaries that have non-controlling interests that are material to the Group: None.

(4) Foreign currency translation

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The consolidated financial statements are presented in NTD, which is the Company's functional and the Group's presentation currency.

A. Foreign currency transactions and balances

- (a) Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are remeasured. Foreign exchange gains and losses resulting from the settlement of such transactions are recognised in profit or loss in the period in which they arise.
- (b) Monetary assets and liabilities denominated in foreign currencies at the period end are re-translated at the exchange rates prevailing at the balance sheet date. Exchange differences arising upon re-translation at the balance sheet date are recognised in profit or loss.
- (c) Non-monetary assets and liabilities denominated in foreign currencies held at fair value through profit or loss are re-translated at the exchange rates prevailing at the balance sheet date; their translation differences are recognised in profit or loss. Non-monetary assets and liabilities denominated in foreign currencies held at fair value through other comprehensive income are re-translated at the exchange rates prevailing at the balance sheet date; their translation differences are recognised in other comprehensive income. However, non-monetary assets and liabilities denominated in foreign currencies that are not measured at fair value are translated using the historical exchange rates at the dates of the initial transactions.
- (d) All other foreign exchange gains and losses are presented in the statement of comprehensive income within "other gains and losses".

B. Translation of foreign operations

- (a) The operating results and financial position of all the group entities, associates and joint arrangements that have a functional currency different from the presentation currency are translated into the presentation currency as follows:
 - i. Assets and liabilities for each balance sheet presented are translated at the closing exchange rate at the date of that balance sheet;
 - ii. Income and expenses for each statement of comprehensive income are translated at average exchange rates of that period; and
 - iii. All resulting exchange differences are recognised in other comprehensive income.
- (b) When the foreign operation partially disposed of or sold is a subsidiary, cumulative exchange differences that were recorded in other comprehensive income are proportionately transferred to the non-controlling interest in this foreign operation. In addition, if the Group retains partial interest in the former foreign subsidiary after losing control of the former foreign subsidiary, such transactions should be accounted for as disposal of all interest in the foreign operation.

(5) Classification of current and non-current items

- A. Assets that meet one of the following criteria are classified as current assets; otherwise they are classified as non-current assets:
- (a) Assets that are expected to be realised, or are intended to be sold or consumed in the normal operating cycle;
 - (b) Assets held primarily for the purpose of trading;
 - (c) Assets that are expected to be realised within 12 months after the reporting period;
 - (d) Cash and cash equivalents, excluding restricted cash and cash equivalents and those that are to be exchanged or used to pay off liabilities for at least 12 months after the reporting period.
- B. Liabilities that meet one of the following criteria are classified as current liabilities; otherwise they are classified as non-current liabilities:
- (a) Liabilities that are expected to be settled in the normal operating cycle;
 - (b) Liabilities arising primarily from trading activities;
 - (c) Liabilities that are due to be settled within 12 months after the reporting period;
 - (d) It does not have the right at the end of the reporting period to defer settlement of the liability at least 12 months after the reporting period.

(6) Cash equivalents

- A. Cash equivalents refer to short-term highly liquid investments that are readily convertible to known amount of cash and subject to an insignificant risk of changes in value.
- B. Time deposits and bills under repurchase agreements that meet the above criteria and are held for the purpose of meeting short-term cash commitment in operations are classified as cash equivalents.
- C. The Group holds pledged time deposits that do not qualify as cash equivalents, listed as “Other Financial Assets”.

(7) Financial assets at fair value through profit or loss

- A. Financial assets at fair value through profit or loss are financial assets that are not measured at amortised cost or fair value through other comprehensive income.
- B. On a regular way purchase or sale basis, financial assets at fair value through profit or loss are recognised and derecognised using trade date accounting.
- C. At initial recognition, the Group measures the financial assets at fair value and recognises the transaction costs in profit or loss. The Group subsequently measures the financial assets at fair value, and recognises the gain or loss in profit or loss.
- D. The Group recognises the dividend income when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

(8) Financial assets at fair value through other comprehensive income

- A. Financial assets at fair value through other comprehensive income comprise equity securities which are not held for trading, and for which the Group has made an irrevocable election at initial recognition to recognise changes in fair value in other comprehensive income.
- B. On a regular way purchase or sale basis, financial assets at fair value through other comprehensive income are recognised and derecognised using trade date accounting.
- C. At initial recognition, the Group measures the financial assets at fair value plus transaction costs. The Group subsequently measures the financial assets at fair value. The changes in fair value of equity investments that were recognised in other comprehensive income are reclassified to retained earnings and are not reclassified to profit or loss following the derecognition of the investment. Dividends are recognised as revenue when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

(9) Accounts and notes receivable

- A. Accounts and notes receivable entitle the Group a legal right to receive consideration in exchange for transferred goods or rendered services.
- B. The short-term accounts and notes receivable without bearing interest are subsequently measured at initial invoice amount as the effect of discounting is immaterial.

(10) Impairment of financial assets

For financial assets at amortised cost, at each reporting date, the Group recognises the impairment provision for 12 months expected credit losses if there has not been a significant increase in credit risk since initial recognition or recognises the impairment provision for the lifetime expected credit losses (ECLs) if such credit risk has increased since initial recognition after taking into consideration all reasonable and verifiable information that includes forecasts. On the other hand, for accounts receivable or contract assets that do not contain a significant financing component, the Group recognises the impairment provision for lifetime ECLs.

(11) Derecognition of financial assets

The Group derecognises a financial asset when the contractual rights to receive the cash flows from the financial asset expire.

(12) Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined using the weighted-average method. The cost of finished goods and work in progress comprises raw materials, direct labour, other direct costs and related production overheads (allocated based on normal operating capacity). It excludes borrowing costs. The item by item approach is used in applying the lower of cost and net realisable value. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. If the cost exceeds net realisable value, valuation loss is accrued and recognised in operating costs. If the net realisable value reverses, valuation is eliminated within the credit balance and is recognised as deduction of operating costs.

(13) Property, plant and equipment

- A. Property, plant and equipment are initially recorded at cost. Borrowing costs incurred during the construction period are capitalised.
- B. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.
- C. Property, plant and equipment apply cost model and are depreciated using the straight-line method to allocate their cost over their estimated useful lives. If each component of property, plant and equipment is significant, it is depreciated separately.
- D. The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each financial year-end date. If expectations for the assets' residual values and useful lives differ from previous estimates or the patterns of consumption of the assets' future economic benefits embodied in the assets have changed significantly, any change is accounted for as a change in estimate under IAS 8, 'Accounting Policies, Changes in Accounting Estimates and Errors', from the date of the change. The estimated useful lives of property, plant and equipment are as follows:

<u>Assets</u>	<u>Estimated useful lives</u>
Buildings and structures	2 ~ 35 years
Machinery and equipment	2 ~ 12 years
Transportation equipment	2 ~ 5 years
Office equipment	2 ~ 9 years
Other equipment	2 ~ 19 years

(14) Intangible assets

Professional skills and computer software, etc. are stated at cost and amortised on a straight-line basis over their estimated useful lives of 3 ~ 10 years.

(15) Leasing arrangements (lessee) – right-of-use assets/lease liabilities

- A. Leases are recognised as a right-of-use asset and a corresponding lease liability at the date at which the leased asset is available for use by the Group. For short-term leases or leases of low-value assets, lease payments are recognised as an expense on a straight-line basis over the lease term.
- B. Lease liabilities include the net present value of the remaining lease payments at the commencement date, discounted using the incremental borrowing interest rate. Lease payments are fixed payments less any lease incentives receivable. The Group subsequently measures the lease liability at amortised cost using the interest method and recognises interest expense over the lease term. The lease liability is remeasured and the amount of remeasurement is recognised as an adjustment to the right-of-use asset when there are changes in the lease term or lease payments and such changes do not arise from contract modifications.
- C. At the commencement date, the right-of-use asset is stated at cost under the amount of the initial measurement of lease liability. The right-of-use asset is measured subsequently using the cost model and is depreciated from the commencement date to the earlier of the end of the asset's useful life or the end of the lease term. When the lease liability is remeasured, the amount of remeasurement is recognised as an adjustment to the right-of-use asset.
- D. For lease modifications that decrease the scope of the lease, the lessee shall decrease the carrying amount of the right-of-use asset and remeasure the lease liability to reflect the partial or full termination of the lease, and recognise the difference in profit or loss. For all other lease modifications, the lessee shall remeasure the lease liability and adjust the right-of-use asset, correspondingly.

(16) Impairment of non-financial assets

The Group assesses at each balance sheet date the recoverable amounts of those assets where there is an indication that they are impaired. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell or value in use. When the circumstances or reasons for recognising impairment loss for an asset in prior years no longer exist or diminish, the impairment loss shall be reversed to the extent of the loss previously recognised in profit or loss. The increased carrying amount due to reversal should not be more than what the depreciated or amortised historical cost would have been if the impairment had not been recognised.

(17) Borrowings

Borrowings comprise long-term and short-term bank borrowings. Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in profit or loss over the period of the borrowings using the effective interest method.

(18) Financial liabilities at fair value through profit or loss

A. Financial liabilities are classified in this category of held for trading if acquired principally for the purpose of repurchasing in the short-term. Derivatives are also categorised as financial liabilities held for trading unless they are designated as hedges or financial liabilities at fair value through profit or loss. Financial liabilities that meet one of the following criteria are designated as at fair value through profit or loss at initial recognition:

- (a) Hybrid (combined) contracts; or
- (b) They eliminate or significantly reduce a measurement or recognition inconsistency; or
- (c) They are managed and their performance is evaluated on a fair value basis, in accordance with a documented risk management policy.

B. At initial recognition, the Group measures the financial liabilities at fair value. All related transaction costs are recognised in profit or loss. The Group subsequently measures these financial liabilities at fair value with any gain or loss recognised in profit or loss.

(19) Notes and accounts payable

A. Accounts payable are liabilities for purchases of raw materials, goods or services and notes payable are those resulting from operating and non-operating activities.

B. The short-term notes and accounts payable without bearing interest are subsequently measured at initial invoice amount as the effect of discounting is immaterial.

(20) Derecognition of financial liabilities

A financial liability is derecognised when the obligation under the liability specified in the contract is discharged, cancelled or expires.

(21) Offsetting financial instruments

Financial assets and liabilities are offset and reported in the net amount in the balance sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously.

(22) Employee benefits

A. Short-term employee benefits

Short-term employee benefits are measured at the undiscounted amount of the benefits expected to be paid in respect of service rendered by employees in a period and should be recognised as expenses in that period when the employees render service.

B. Pensions

(a) Defined contribution plans

For defined contribution plans, the contributions are recognised as pension expenses when they are due on an accrual basis. Prepaid contributions are recognised as an asset to the extent of a cash refund or a reduction in the future payments.

(b) Defined benefit plans

- i. Net obligation under a defined benefit plan is defined as the present value of an amount of pension benefits that employees will receive on retirement for their services with the Group in current period or prior periods. The liability recognised in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The net defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The rate used to discount is determined by using interest of government bonds (at the balance sheet date) of a currency and term consistent with the currency and term of the employment benefit obligations.
- ii. Remeasurements arising on defined benefit plans are recognised in other comprehensive income in the period in which they arise, and recorded as retained earnings.

C. Employees' compensation and directors' remuneration

Employees' compensation and directors' remuneration are recognised as expenses and liability, provided that such recognition is required under legal or constructive obligation and those amounts can be reliably estimated. Any difference between the resolved amounts and the subsequently actual distributed amounts is accounted for as changes in estimates. If employees' compensation is distributed by shares, the Group calculates the number of shares based on the closing market price at the previous day of the board meeting resolution.

(23) Employee share-based payment

For the equity-settled share-based payment arrangements, the employee services received are measured at the fair value of the equity instruments granted at the grant date, and are recognised as compensation cost over the vesting period, with a corresponding adjustment to equity. The fair value of the equity instruments granted shall reflect the impact of market vesting conditions and non-market vesting conditions. Compensation cost is subject to adjustment based on the service conditions that are expected to be satisfied and the estimates of the number of equity instruments that are expected to vest under the non-market vesting conditions at each balance sheet date. Ultimately, the amount of compensation cost recognised is based on the number of equity instruments that eventually vest.

(24) Income tax

- A. The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or items recognised directly in equity, in which cases the tax is recognised in other comprehensive income or equity.
- B. The current income tax expense is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Group operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in accordance with applicable tax regulations. It establishes provisions where appropriate based on the amounts expected to be paid to the tax authorities. An additional tax is levied on the unappropriated retained earnings and is recorded as income tax expense in the year the stockholders resolve to retain the earnings.
- C. Deferred income tax is recognised, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, the deferred income tax is not accounted for if it arises from initial recognition of goodwill or of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss and does not give rise to equal taxable and deductible temporary differences. Deferred income tax is provided on temporary differences arising on investments in subsidiaries except where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.
- D. Deferred income tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. At each balance sheet date, unrecognised and recognised deferred income tax assets are reassessed.
- E. Current income tax assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. Deferred tax assets and liabilities are offset on the balance sheet when the entity has the legally enforceable right to offset current tax assets against current tax liabilities and they are levied by the same taxation authority on either the same entity or different entities that intend to settle on a net basis or realise the asset and settle the liability simultaneously.

(25) Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or stock options are shown in equity as a deduction, net of tax, from the proceeds.

(26) Dividends

Dividends are recorded in the Company's financial statements in the period in which they are resolved by the Company's shareholders. Cash dividends are recorded as liabilities; stock dividends are recorded as stock dividends to be distributed and are reclassified to ordinary shares on the effective date of new shares issuance.

(27) Revenue recognition

A. Sales of goods

- (a) The Group manufactures and sells API, intermediates, etc. Sales are recognised when control of the products has transferred, and there is no unfulfilled obligation that could affect the customer's acceptance of the products. Delivery occurs when the products have been shipped to the specific location, the risks of obsolescence and loss have been transferred to the customer, and either the customer has accepted the products in accordance with the sales contract, or the Group has objective evidence that all criteria for acceptance have been satisfied.
- (b) Revenue is recognised based on the price specified in the contract, net of the sales returns and discounts. Accumulated experience is used to estimate and provide for the sales returns and discounts, using the expected value method, and revenue is only recognised to the extent that it is highly probable that a significant reversal will not occur. The estimation is subject to an assessment at each reporting date. As the time interval between the transfer of committed goods or service and the payment of customer does not exceed one year, the Group does not adjust the transaction price to reflect the time value of money.
- (c) A receivable is recognised when the goods are delivered as this is the point in time that the consideration is unconditional because only the passage of time is required before the payment is due.

B. Sales of services

- (a) The Group provides technology development and consultation services. Revenue from providing services is recognised in the accounting period in which the services are rendered. For fixed-price contracts, revenue is recognised based on the service rendered up to the end of the reporting period as a proportion of the total services to be provided. The customer pays at the time specified in the payment schedule. If the services rendered exceed the payment, a contract asset is recognised. If the payments exceed the services rendered, a contract liability is recognised.
- (b) The Group's estimate about revenue, costs and progress towards complete satisfaction of a performance obligation is subject to a revision whenever there is a change in circumstances. Any increase or decrease in revenue or costs due to an estimate revision is reflected in profit or loss during the period when the management becomes aware of the changes in circumstances.

C. Incremental costs of obtaining a contract

Given that the contractual period lasts less than one year, the Group recognises the incremental costs (mainly comprised of sales commissions) of obtaining a contract as an expense when incurred although the Group expects to recover those costs.

(28) Government grants

Government grants are recognised at their fair value only when there is reasonable assurance that the Group will comply with any conditions attached to the grants and the grants will be received. Government grants are recognised in profit or loss on a systematic basis over the periods in which the Group recognises expenses for the related costs for which the grants are intended to compensate.

(29) Operating segments

Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision-Maker. The Chief Operating Decision-Maker is responsible for allocating resources and assessing performance of the operating segments.

5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

The preparation of these consolidated financial statements requires management to make critical judgements in applying the Group's accounting policies and make critical assumptions and estimates concerning future events. Assumptions and estimates may differ from the actual results and are continually evaluated and adjusted based on historical experience and other factors. Such assumptions and estimates have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, and the related information is addressed below.

(1) Critical judgements in applying the Group's accounting policies

None.

(2) Critical accounting estimates and assumptions

A. Evaluation of inventories

(a) As inventories are stated at the lower of cost and net realisable value, the Group must determine the net realisable value of inventories on balance sheet date using judgements and estimates. As the manufacturing process is relatively complicated and time consuming, materials require longer lead time, the waiting period for product registration is long, and the timing of customers' product launch may be deferred, the Group evaluates the amounts of normal inventory consumption, obsolete inventories or inventories without market selling value on balance sheet date, and writes down the cost of inventories to the net realisable value. Since the calculation of net realisable value involves subjective judgement and the ending balance of inventory is material to the financial statements, there might be material changes to the evaluation.

(b) As of December 31, 2025, the carrying amount of inventories was \$1,636,540.

B. Realisability of deferred income tax assets

(a) Deferred income tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences can be utilized. Assessment of the realisability of deferred income tax assets involves critical accounting judgments and estimates of the management, including the assumptions of expected future sales revenue growth rate and profit rate, tax exempt duration, available tax credits, tax planning, etc. Any variations in global economic environment, industrial environment, and laws and regulations might cause material adjustments to deferred income tax assets.

(b) As of December 31, 2025, the Group recognised deferred income tax assets amounting to \$664,626.

6. DETAILS OF SIGNIFICANT ACCOUNTS

(1) CASH AND CASH EQUIVALENTS

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Cash:		
Cash on hand	\$ 123	\$ 129
Checking accounts and demand deposits	<u>116,451</u>	<u>167,117</u>
	<u>116,574</u>	<u>167,246</u>
Cash equivalents:		
Time deposits	2,788,500	3,833,741
Bills under repurchase agreements	<u>205,000</u>	<u>165,000</u>
	<u>2,993,500</u>	<u>3,998,741</u>
	<u>\$ 3,110,074</u>	<u>\$ 4,165,987</u>

A. The Group transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.

B. Details of the Group's time deposits pledged to others as collateral (listed as "Other financial assets - non-current") as of December 31, 2025 and 2024 are provided in Note 8, "Pledged assets".

(2) FINANCIAL ASSETS AND LIABILITIES AT FAIR VALUE THROUGH PROFIT OR LOSS

Items	December 31, 2025	December 31, 2024
Current items:		
Financial assets (liabilities) mandatorily measured at fair value through profit or loss		
Derivatives	\$ 90	(\$ 1,225)
Non-current items:		
Financial assets mandatorily measured at fair value through profit or loss		
Unlisted stocks	\$ 4,620	\$ 4,620
Valuation adjustment	(4,620)	(4,620)
	\$ -	\$ -

- A. The Group recognised net loss of \$5,810 and \$29,294 on financial assets and liabilities at fair value through profit or loss (listed as“Other gains and losses”) for the years ended December 31, 2025 and 2024, respectively.
- B. The Group entered into contracts relating to derivative financial assets and liabilities which were not accounted for under hedge accounting. The information is listed below (Units in thousands of currencies indicated):

Items	December 31, 2025	
	Contract amount	Contract period
Forward foreign exchange contracts	USD 8,950	11.2025~3.2026

Items	December 31, 2024	
	Contract amount	Contract period
Forward foreign exchange contracts	USD 7,830	11.2024~2.2025

The Group entered into forward foreign exchange contracts to hedge exchange rate risk of operating activities. However, these forward foreign exchange contracts are not accounted for under hedge accounting.

- C. The Group has no financial assets at fair value through profit or loss pledged to others as of December 31, 2025 and 2024.

(3) ACCOUNTS RECEIVABLE, NET

	December 31, 2025	December 31, 2024
Accounts receivable	\$ 614,274	\$ 606,123
Less: Loss allowance	(1,863)	(1,904)
	\$ 612,411	\$ 604,219

A. The ageing analysis of accounts receivable is as follows:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Not past due	\$ 570,997	\$ 509,007
Less than 30 days	25,711	94,992
Between 31 to 90 days	-	308
Between 91 to 180 days	17,472	-
Over 181 days	94	1,816
	<u>\$ 614,274</u>	<u>\$ 606,123</u>

The above ageing analysis is based on past due date.

B. As of December 31, 2025 and 2024, accounts receivable arose from contracts with customers. As of January 1, 2024, the balance of receivables from contracts with customers amounted to \$788,452.

C. As of December 31, 2025 and 2024, the Group does not hold any collateral as security.

D. As of December 31, 2025 and 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the Group's accounts receivable was the book value amount.

E. Information relating to credit risk of accounts receivable is provided in Note 12(2), "Financial instruments".

(4) INVENTORIES

	<u>December 31, 2025</u>		
	Cost	Allowance for market price decline	Book value
Raw materials	\$ 314,579	(\$ 55,961)	\$ 258,618
Supplies	89,705	(3,625)	86,080
Work in process	588,897	(121,001)	467,896
Finished goods	1,124,765	(300,819)	823,946
	<u>\$ 2,117,946</u>	<u>(\$ 481,406)</u>	<u>\$ 1,636,540</u>
	<u>December 31, 2024</u>		
	Cost	Allowance for market price decline	Book value
Raw materials	\$ 375,907	(\$ 64,953)	\$ 310,954
Supplies	51,867	(4,639)	47,228
Work in process	658,527	(85,105)	573,422
Finished goods	1,002,857	(261,454)	741,403
	<u>\$ 2,089,158</u>	<u>(\$ 416,151)</u>	<u>\$ 1,673,007</u>

The cost of inventories recognised as expense for the year:

	For the years ended December 31,	
	2025	2024
Cost of goods sold	\$ 1,366,583	\$ 1,499,892
Loss on scrap inventory	40,633	42,483
Loss on physical inventory	601	867
Under applied manufacturing overhead	485,456	447,603
Loss on inventory market price decline	65,207	9,978
Revenue from sale of scraps	(1,951)	(1,836)
	<u>\$ 1,956,529</u>	<u>\$ 1,998,987</u>

(5) FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME - NON-CURRENT

Items	December 31, 2025	December 31, 2024
Equity instruments		
Emerging stocks	\$ 1,156,000	\$ -
Unlisted stocks	167,673	167,673
	1,323,673	167,673
Valuation adjustment	44,065	(97,539)
	<u>\$ 1,367,738</u>	<u>\$ 70,134</u>

A. The Group has elected to classify investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments is the book value as of December 31, 2025 and 2024.

B. Amounts recognised in other comprehensive income in relation to the financial assets at fair value through other comprehensive income are listed below:

	For the years ended December 31,	
	2025	2024
Equity instruments at fair value through other comprehensive income		
Fair value change recognised in other comprehensive income	\$ 141,604	\$ 161
Dividend income recognised in profit or loss	\$ 25,615	\$ -

C. The Group has no financial assets at fair value through other comprehensive income pledged to others as of December 31, 2025 and 2024.

(6) PROPERTY, PLANT AND EQUIPMENT

	Buildings	Machinery and equipment	Transportation equipment	Office equipment	Other equipment	Construction in progress and equipment before acceptance inspection	Total
<u>January 1, 2025</u>							
Cost	\$ 4,309,016	\$ 6,194,785	\$ 29,299	\$ 254,278	\$ 173,026	\$ 194,044	\$ 11,154,448
Accumulated depreciation	(2,074,839)	(4,976,305)	(22,930)	(198,727)	(138,624)	-	(7,411,425)
Accumulated impairment	-	(4,134)	-	-	-	-	(4,134)
	<u>\$ 2,234,177</u>	<u>\$ 1,214,346</u>	<u>\$ 6,369</u>	<u>\$ 55,551</u>	<u>\$ 34,402</u>	<u>\$ 194,044</u>	<u>\$ 3,738,889</u>
<u>For the year ended December 31, 2025</u>							
At January 1	\$ 2,234,177	\$ 1,214,346	\$ 6,369	\$ 55,551	\$ 34,402	\$ 194,044	\$ 3,738,889
Additions	733	704	-	1,314	-	81,599	84,350
Reclassified from prepayments for equipment	-	-	-	-	-	69,705	69,705
Reclassified upon completion	8,652	240,979	142	29,774	2,311	(281,858)	-
Reclassified to intangible assets	-	-	-	-	-	(1,278)	(1,278)
Reclassified to other non-current assets	-	-	-	-	-	(5,755)	(5,755)
Depreciation charge	(187,844)	(259,536)	(1,905)	(22,658)	(3,728)	-	(475,671)
Disposals – Cost	(1,688)	(37,856)	(2,025)	(25,264)	(3,976)	-	(70,809)
– Accumulated depreciation	779	37,613	1,977	25,213	3,579	-	69,161
Reversal of impairment loss	-	2,251	-	-	-	-	2,251
Net currency exchange differences	(538)	2,485	(40)	427	(14)	(4,381)	(2,061)
At December 31	<u>\$ 2,054,271</u>	<u>\$ 1,200,986</u>	<u>\$ 4,518</u>	<u>\$ 64,357</u>	<u>\$ 32,574</u>	<u>\$ 52,076</u>	<u>\$ 3,408,782</u>
<u>December 31, 2025</u>							
Cost	\$ 4,318,268	\$ 6,404,032	\$ 27,410	\$ 260,884	\$ 171,521	\$ 52,076	\$ 11,234,191
Accumulated depreciation	(2,263,997)	(5,201,164)	(22,892)	(196,527)	(138,947)	-	(7,823,527)
Accumulated impairment	-	(1,882)	-	-	-	-	(1,882)
	<u>\$ 2,054,271</u>	<u>\$ 1,200,986</u>	<u>\$ 4,518</u>	<u>\$ 64,357</u>	<u>\$ 32,574</u>	<u>\$ 52,076</u>	<u>\$ 3,408,782</u>

	Buildings	Machinery and equipment	Transportation equipment	Office equipment	Other equipment	Construction in progress and equipment before acceptance inspection	Total
<u>January 1, 2024</u>							
Cost	\$ 4,249,075	\$ 5,998,911	\$ 26,907	\$ 244,141	\$ 165,103	\$ 77,715	\$ 10,761,852
Accumulated depreciation	(1,875,104)	(4,772,711)	(21,402)	(195,193)	(131,732)	-	(6,996,142)
Accumulated impairment	-	(3,014)	-	-	-	-	(3,014)
	<u>\$ 2,373,971</u>	<u>\$ 1,223,186</u>	<u>\$ 5,505</u>	<u>\$ 48,948</u>	<u>\$ 33,371</u>	<u>\$ 77,715</u>	<u>\$ 3,762,696</u>
<u>For the year ended December 31, 2024</u>							
At January 1	\$ 2,373,971	\$ 1,223,186	\$ 5,505	\$ 48,948	\$ 33,371	\$ 77,715	\$ 3,762,696
Additions	-	136	-	18	-	160,935	161,089
Reclassified from prepayments for equipment	-	-	-	-	-	245,852	245,852
Reclassified upon completion	28,697	233,147	2,480	23,559	3,605	(291,488)	-
Depreciation charge	(189,045)	(249,721)	(1,742)	(17,593)	(3,444)	-	(461,545)
Disposals — Cost	(9,319)	(56,614)	(351)	(16,251)	(1,669)	-	(84,204)
— Accumulated depreciation	2,050	53,185	351	16,226	1,538	-	73,350
Transferred to expenses — Cost	-	(10,528)	-	-	-	-	(10,528)
— Accumulated depreciation	-	10,409	-	-	-	-	10,409
Impairment loss	-	(1,119)	-	-	-	-	(1,119)
Net currency exchange differences	27,823	12,265	126	644	1,001	1,030	42,889
At December 31	<u>\$ 2,234,177</u>	<u>\$ 1,214,346</u>	<u>\$ 6,369</u>	<u>\$ 55,551</u>	<u>\$ 34,402</u>	<u>\$ 194,044</u>	<u>\$ 3,738,889</u>
<u>December 31, 2024</u>							
Cost	\$ 4,309,016	\$ 6,194,785	\$ 29,299	\$ 254,278	\$ 173,026	\$ 194,044	\$ 11,154,448
Accumulated depreciation	(2,074,839)	(4,976,305)	(22,930)	(198,727)	(138,624)	-	(7,411,425)
Accumulated impairment	-	(4,134)	-	-	-	-	(4,134)
	<u>\$ 2,234,177</u>	<u>\$ 1,214,346</u>	<u>\$ 6,369</u>	<u>\$ 55,551</u>	<u>\$ 34,402</u>	<u>\$ 194,044</u>	<u>\$ 3,738,889</u>

- A. The Group has not capitalised borrowing costs as part of property, plant and equipment for the years ended December 31, 2025 and 2024.
- B. The Group’s property, plant and equipment were owner-occupied for the years ended December 31, 2025 and 2024.
- C. Information about reversal of impairment loss and impairment loss on property, plant and equipment is provided in Note 6(8).
- D. As of December 31, 2025 and 2024, the Group has not pledged any property, plant and equipment as collateral.

(7) LEASING ARRANGEMENTS – LESSEE

- A. The Group leases land and buildings and structures. Rental contracts are typically made for periods of 50 (including the option to extend the leases) and 2 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions, with no restrictions other than the use of the subject matter of the lease in accordance with relevant laws and regulations.
- B. Short-term leases with a lease term of 12 months or less pertain to office premises and low-value assets pertain to computers.
- C. The carrying amount of right-of-use assets and the depreciation charge are as follows:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
	<u>Carrying amount</u>	<u>Carrying amount</u>
Land	\$ 668,466	\$ 684,290
Buildings and structures	5,812	2,345
	<u>\$ 674,278</u>	<u>\$ 686,635</u>
	<u>For the years ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
	<u>Depreciation charge</u>	<u>Depreciation charge</u>
Land	\$ 15,846	\$ 15,899
Buildings and structures	4,774	1,342
	<u>\$ 20,620</u>	<u>\$ 17,241</u>

- D. For the years ended December 31, 2025 and 2024, the additions to right-of-use assets were \$8,241 and \$2,680, respectively; the remeasurements of right-of-use assets were \$ – and \$61,985, respectively.

E. The information on profit and loss accounts relating to lease contracts is as follows:

	For the years ended December 31,	
	2025	2024
<u>Items affecting profit or loss</u>		
Interest expense on lease liabilities	\$ 7,282	\$ 7,292
Expense on short-term lease contracts	986	730
Expense on leases of low-value assets	3,162	4,014

F. For the years ended December 31, 2025 and 2024, the Group's total cash outflow for leases were \$27,413 and \$24,508, respectively.

(8) IMPAIRMENT OF NON-FINANCIAL ASSETS

A. The Group recognised the gain on reversal of (impairment loss) amounting to \$2,251 and (\$1,119) for the years ended December 31, 2025 and 2024, respectively (listed as "Other gains and losses"). For details of accumulated impairment, refer to Note 6(6).

B. The gain on reversal of (impairment loss) reported by operating segments is as follows:

Segment	For the years ended December 31,			
	2025		2024	
	Recognised in profit or loss	Recognised in other comprehensive income	Recognised in profit or loss	Recognised in other comprehensive income
ScinoPharm Taiwan, Ltd.	\$ 2,251	\$ -	(\$ 1,119)	\$ -

(9) SHORT-TERM BORROWINGS

Type of borrowings	December 31, 2025	Interest rate	Collateral
Bank loans			
Unsecured loans	\$ 130,424	2.60%~2.80%	None
Type of borrowings	December 31, 2024	Interest rate	Collateral
Bank loans			
Unsecured loans	\$ 35,563	2.90%~3.00%	None

Refer to Note 6(21), "Finance costs" for interest expense recognised in profit or loss for the years ended December 31, 2025 and 2024.

(10) OTHER PAYABLES

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Accrued salaries and bonuses	\$ 88,609	\$ 96,725
Payables on equipment	62,226	154,222
Accrued employees' compensation and directors' remuneration	16,924	46,723
Others	<u>195,822</u>	<u>200,521</u>
	<u>\$ 363,581</u>	<u>\$ 498,191</u>

(11) PENSIONS

A. The Company has set up a defined benefit pension plan in accordance with the Labor Standards Law, which applies to all regular employees' service years prior to the enforcement of the Labor Pension Act (the "Act") on July 1, 2005 and service years thereafter of employees who chose to continue to be covered under the pension scheme of the Labor Standards Law after the enforcement of the Act. In accordance with the Company's retirement plan, an employee may retire when the employee either (i) attains the age of 55 with 15 years of service, (ii) has more than 25 years of service, (iii) has reached the age of 65, or (iv) is incapacitated to work (compulsory retirement). The employees earn two units for each year of service for the first 15 years, and one unit for each additional year thereafter up to a maximum of 45 units. Any fraction of a year equal to or more than six months shall be counted as one year of service, and any fraction of a year less than six months shall be counted as half a year. According to the provisions, employees who retired due to their duties shall get additional 20%. Pension payments are based on the number of units earned and the average salary of the last six months prior to retirement. Calculation of average salary is in accordance with the Labor Standards Law of the R.O.C. The Company contributes monthly an amount equal to 2% of the employees' monthly salaries and wages to the retirement fund deposited with Bank of Taiwan under the name of the independent retirement fund committee. Also, the Company would assess the balance in the aforementioned labor pension reserve account by December 31, every year. If the account balance is not enough to pay the pension calculated by the aforementioned method to the employees expected to qualify for retirement in the following year, the Company will make contribution for the deficit by end of March next year.

(a) The amounts recognised in the balance sheet are as follows:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Present value of defined benefit obligations	\$ 103,632	\$ 99,288
Fair value of plan assets	(92,938)	(75,674)
Net defined benefit liability	<u>\$ 10,694</u>	<u>\$ 23,614</u>

distributions on the final financial statements shall be no less than the earnings attainable from the amounts accrued from two-year time deposits with the interest rates offered by local banks. If the earnings is less than aforementioned rates, government shall make payment for the deficit after being authorised by the Regulator. The Company has no right to participate in managing and operating that fund and hence the Company is unable to disclose the classification of plan asset fair value in accordance with IAS 19 paragraph 142. The composition of fair value of plan assets as of December 31, 2025 and 2024 is given in the Annual Labor Retirement Fund Utilisation Report announced by the government.

(d) The principal actuarial assumptions used were as follows:

	<u>For the years ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Discount rate	<u>1.30%</u>	<u>1.60%</u>
Future salary increases	<u>1.00%</u>	<u>1.00%</u>

Assumptions regarding future mortality experience are set based on actuarial advice in accordance with published statistics and experience according to Taiwan Life Insurance Industry 6th Mortality Table for the years ended December 31, 2025 and 2024.

Because the main actuarial assumption changed, the present value of defined benefit obligation is affected. The analysis was as follows:

	<u>Discount rate</u>		<u>Future salary increases</u>	
	<u>Increase 0.25%</u>	<u>Decrease 0.25%</u>	<u>Increase 0.25%</u>	<u>Decrease 0.25%</u>
<u>December 31, 2025</u>				
Effect on present value of defined benefit obligation	(\$ <u>1,745</u>)	<u>\$ 1,793</u>	<u>\$ 1,533</u>	(\$ <u>1,501</u>)
<u>December 31, 2024</u>				
Effect on present value of defined benefit obligation	(\$ <u>1,831</u>)	<u>\$ 1,883</u>	<u>\$ 1,639</u>	(\$ <u>1,604</u>)

The sensitivity analysis above was based on one assumption which changed while the other conditions remain unchanged. In practice, more than one assumption may change all at once. The method of analysing sensitivity and the method of calculating net pension liability in the balance sheet are the same.

The methods and types of assumptions used in preparing the sensitivity analysis did not change compared to the previous year.

(e) Expected contributions to the defined benefit pension plan of the Company for 2026 amount to \$2,852.

(f) As of December 31, 2025, the weighted average duration of that retirement plan is 7 years.

The analysis of timing of the future pension payment was as follows:

Within 1 year	\$	7,497
2~5 years		40,151
Over 6 years		65,874
	<u>\$</u>	<u>113,522</u>

B. As a result of the enforcement of the Act, the Company set up a defined contribution pension plan which took effect on July 1, 2005. The local employees are eligible for the defined contribution plan. For employees who choose to be covered under the pension scheme of the Act, the Company contributes monthly an amount of not less than 6% of the employees' monthly salaries and wages to the employees' individual pension accounts at the Bureau of Labor Insurance. Pensions are paid by monthly installments or in lump sum based on the accumulated balances of the employees' individual pension accounts. The subsidiaries in Mainland China (SciAnda (Changshu) Pharmaceuticals, Ltd., and SciAnda Shanghai Biochemical Technology, Ltd.) are subject to a government sponsored defined contribution plan. In accordance with the related Laws of the People's Republic of China, the subsidiaries in Mainland China contribute monthly 18% of the employees' monthly salaries and wages to an independent fund administered by the government. Other than the monthly contributions, these subsidiaries do not have further obligations. The other subsidiaries, SPT International, Ltd. and ScinoPharm Singapore Pte Ltd., had no employees. For the years ended December 31, 2025 and 2024, the pension costs recognised under the aforementioned defined contribution pension plans were \$43,401 and \$41,982, respectively.

(12) SHARE CAPITAL

A. Movements in the number of the Company's ordinary shares outstanding are as follows (in thousands of shares):

	<u>For the years ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
At January 1 and December 31	<u>790,739</u>	<u>790,739</u>

B. As of December 31, 2025, the Company's authorised capital was \$10,000,000, and the paid-in capital was \$7,907,392 (790,739 thousand shares) with a par value of \$10 (in dollars) per share. All proceeds from shares issued have been collected.

(13) CAPITAL RESERVES

A. Pursuant to the R.O.C. Company Act, capital reserve arising from paid-in capital in excess of par value on issuance of common stocks and donations shall be exclusively used to cover accumulated deficit or, distribute cash or stocks in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Act requires that the capital reserve to be capitalised mentioned above should not exceed 10% of the paid-in capital each year. Capital reserve should not be used to cover accumulated deficit unless the legal reserve is insufficient.

B. Movements on the Company's capital reserve are as follows:

	<u>For the year ended December 31, 2025</u>		
	<u>Share premium</u>	<u>Stock options</u>	<u>Total</u>
At January 1	\$ 1,265,818	\$ 28,871	\$ 1,294,689
Employee stock options forfeited			
- Company	<u>8,792</u>	<u>(8,792)</u>	<u>-</u>
At December 31	<u>\$ 1,274,610</u>	<u>\$ 20,079</u>	<u>\$ 1,294,689</u>

	<u>For the year ended December 31, 2024</u>		
	<u>Share premium</u>	<u>Stock options</u>	<u>Total</u>
At January 1	\$ 1,265,336	\$ 29,353	\$ 1,294,689
Employee stock options forfeited			
- Company	<u>482</u>	<u>(482)</u>	<u>-</u>
At December 31	<u>\$ 1,265,818</u>	<u>\$ 28,871</u>	<u>\$ 1,294,689</u>

(14) SHARE-BASED PAYMENT – EMPLOYEES' COMPENSATION

A. The Company issued 1.5 million units and 1.5 million units of employee stock options on November 6, 2015 and October 14, 2016, respectively (the 'Grant Date'). The exercise price of the options was set at \$41.65 (in dollars) and \$40.55 (in dollars), respectively, which was based on the closing market price of the Company's common shares on the Grant Dates. Each option gives the holder the right to purchase one share of the Company's common stocks. The exercise price is subject to further adjustments when there is a change in the number of shares of the Company's common stocks, the cash dividend of the common stocks is more than 1.5% of the current price per share or there is a decrease in common stocks caused by capital reduction not due to the retirement of treasury share after the Grant Date. Contract period of the employee stock option plans is 10 years, and options are exercisable in 2 years after the Grant Date.

B. Details of the share-based payment arrangements are as follows:

	For the year ended December 31, 2025	
	Number of options (in thousand units)	Weighted-average exercise price (in dollars)
Options outstanding at beginning of the year	1,128	\$ 36.07
Options forfeited	(643)	35.90
Options outstanding at end of the year	485	35.55
Options exercisable at end of the year	485	35.55
	For the year ended December 31, 2024	
	Number of options (in thousand units)	Weighted-average exercise price (in dollars)
Options outstanding at beginning of the year	1,164	\$ 36.07
Options forfeited	(36)	36.13
Options outstanding at end of the year	1,128	36.07
Options exercisable at end of the year	1,128	36.07

C. The expiry date, exercisable shares and exercise prices of the employee stock options at balance sheet date are as follows:

	December 31, 2025		December 31, 2024	
	No. of stocks (unit in thousands)	price (in dollars) (Note)	No. of stocks (unit in thousands)	price (in dollars) (Note)
Grant date	Expiry date			
11.6.2015	11.5.2025	-	515	\$ 35.80
10.14.2016	10.13.2026	485	613	36.30

D. The fair value of the Group's employee stock options on Grant Date was evaluated using the combination of Hull & White and the Ritchken trinomial option valuation model. Related information is as follows:

Type of arrangement	Grant date	Stock price (in dollars)	Exercise price (in dollars)	Price volatility	Option life	Expected dividends	Interest rate	Fair value per unit (in dollars)
Employee stock options	11.6.2015	\$ 41.65	\$ 41.65	37.63% (Note)	10 years	1.5%	1.2936%	\$ 13.799
Employee stock options	10.14.2016	40.55	40.55	37.20% (Note)	10 years	1.5%	0.9223%	13.171

Note: According to daily returns of the Company's stock for the previous year, the annualised volatility were 37.63% and 37.20%, respectively.

(15) RETAINED EARNINGS

- A. Pursuant to the amended R.O.C. Company Act, the current year's after-tax earnings should be used initially to cover any accumulated deficit; thereafter 10% of the remaining earnings should be set aside as legal reserve until the balance of legal reserve is equal to that of paid-in capital. The legal reserve shall be exclusively used to cover accumulated deficit, to issue new stocks, or to distribute cash to shareholders in proportion to their share ownership. The use of legal reserve for the issuance of stocks or cash dividends to shareholders in proportion to their share ownership is permitted provided that the distribution of the reserve is limited to the portion in excess of 25% of the Company's paid-in capital.
- B. According to the Articles of Incorporation of the Company, since the Company is in a changeable industry environment and the life cycle of the Company is in a stable growth, the appropriation of earnings should consider fund requirements and capital budget to decide how much earnings will be kept or distributed and how much cash dividends will be distributed. According to the Company's Articles of Incorporation, 10% of the annual net income, except for offsetting any loss of prior years and paying all taxes and dues according to laws, after adding items other than net profit after taxes for the year into undistributed surplus earnings of current year, 10% of the remaining shall be set aside as legal reserve. The remaining net income and the unappropriated retained earnings from prior years can be distributed in accordance with a resolution passed during a meeting of the Board of Directors and approved at the stockholders' meeting. Of the amount to be distributed by the Company, stockholders' dividends shall comprise 50% to 100% of the unappropriated retained earnings, and the percentage of cash dividends shall not be less than 30% of dividends distributed.
- C. In accordance with the regulations, the Company shall set aside special reserve from the debit balance on other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings. The amounts previously set aside by the Company as special reserve on initial application of IFRSs in accordance with Order No. Financial-Supervisory-Securities-Corporate-1010012865, dated April 6, 2012, shall be reversed proportionately when the relevant assets are used, disposed of or reclassified subsequently. As of December 31, 2025, the amount of special reserve on initial application of IFRSs provided in accordance with the order from Financial Supervisory Committee was \$22,829.
- D. The Company recognised cash dividends distributed to owners amounting to \$276,759 (\$0.35 (in dollars) per share) and \$237,222 (\$0.3 (in dollars) per share) for the years ended December 31, 2025 and 2024, respectively. On March 4, 2026, the Board of Directors proposed for the distribution of cash dividends of \$229,314 (\$0.29 (in dollars) per share) from 2025 earnings.

(16) OTHER EQUITY ITEMS

	For the year ended December 31, 2025		
		Unrealised loss	
	Currency translation	on valuation	Total
At January 1	(\$ 28,638)	(\$ 97,539)	(\$ 126,177)
Revaluation	-	141,604	141,604
Currency translation differences			
- Group	(3,112)	-	(3,112)
At December 31	<u>(\$ 31,750)</u>	<u>\$ 44,065</u>	<u>\$ 12,315</u>

	For the year ended December 31, 2024		
		Unrealised loss	
	Currency translation	on valuation	Total
At January 1	(\$ 88,156)	(\$ 97,700)	(\$ 185,856)
Revaluation	-	161	161
Currency translation differences			
- Group	59,518	-	59,518
At December 31	<u>(\$ 28,638)</u>	<u>(\$ 97,539)</u>	<u>(\$ 126,177)</u>

(17) OPERATING REVENUE

A. Disaggregation of revenue from contracts with customers

The Group derives revenue from the transfer of goods at a point in time and the rendering of services over time in the following major product lines:

For the year ended	API	Injection	Technical	Other	
December 31, 2025	Income	Product	Service	Operating	Total
		Income	Income	Income	
Timing of revenue recognition:					
At a point in time	\$ 2,715,888	\$ 174,554	\$ -	\$ 32,742	\$ 2,923,184
Over time	-	-	240,238	-	240,238
	<u>\$ 2,715,888</u>	<u>\$ 174,554</u>	<u>\$ 240,238</u>	<u>\$ 32,742</u>	<u>\$ 3,163,422</u>

For the year ended	API	Injection	Technical	Other	
December 31, 2024	Income	Product	Service	Operating	Total
		Income	Income	Income	
Timing of revenue recognition:					
At a point in time	\$ 3,021,547	\$ 80,070	\$ -	\$ 44,814	\$ 3,146,431
Over time	-	-	259,853	-	259,853
	<u>\$ 3,021,547</u>	<u>\$ 80,070</u>	<u>\$ 259,853</u>	<u>\$ 44,814</u>	<u>\$ 3,406,284</u>

B. The Group has recognised the following revenue-related contract assets and liabilities:

	December 31, 2025	December 31, 2024	January 1, 2024
Contract assets - current	\$ -	\$ 29,397	\$ -
Contract liabilities - current	\$ 115,351	\$ 119,396	\$ 110,967

C. The revenue recognised that was included in the contract liability balance at the beginning of the year amounted to \$105,280 and \$79,896 for the years ended December 31, 2025 and 2024, respectively.

(18) INTEREST INCOME

	For the years ended December 31,	
	2025	2024
Interest income from bank deposits	\$ 53,376	\$ 61,521

(19) OTHER INCOME

	For the years ended December 31,	
	2025	2024
Dividend income	\$ 25,615	\$ -
Government grants income	1,939	20,601
Income from counterparty default	-	5,498
Production capacity subsidy income	-	1,674
Other income	2,890	2,121
	\$ 30,444	\$ 29,894

(20) OTHER GAINS AND LOSSES

	For the years ended December 31,	
	2025	2024
Net loss on financial assets/liabilities at fair value through profit or loss	(\$ 5,810)	(\$ 29,294)
Gain on reversal of (impairment loss)	2,251	(1,119)
Loss on disposal of property, plant and equipment	(185)	(4,636)
Net currency exchange (loss) gain	(24,201)	48,519
Others	(7,539)	(4,826)
	\$ 35,484	\$ 8,644

(21) FINANCE COSTS

	For the years ended December 31,	
	2025	2024
Interest expense:		
Bank loans	\$ 2,585	\$ 791
Interest on lease liabilities	7,282	7,292
	<u>\$ 9,867</u>	<u>\$ 8,083</u>

(22) EXPENSES BY NATURE

	For the year ended December 31, 2025		
	Operating costs	Operating expenses	Total
Employee benefit expenses	\$ 641,265	\$ 347,488	\$ 988,753
Depreciation of property, plant and equipment	404,887	70,784	475,671
Depreciation of right-of-use assets	-	20,620	20,620
Amortisation	3,703	16,734	20,437
	For the year ended December 31, 2024		
	Operating costs	Operating expenses	Total
Employee benefit expenses	\$ 665,737	\$ 345,257	\$ 1,010,994
Depreciation of property, plant and equipment	392,437	69,108	461,545
Depreciation of right-of-use assets	-	17,241	17,241
Amortisation	2,776	6,719	9,495

(23) EMPLOYEE BENEFIT EXPENSES

	For the year ended December 31, 2025		
	Operating costs	Operating expenses	Total
Salaries and wages	\$ 533,957	\$ 288,557	\$ 822,514
Labor and health insurance expenses	49,558	23,459	73,017
Pension costs	30,350	14,197	44,547
Other personnel expenses	27,400	21,275	48,675
	<u>\$ 641,265</u>	<u>\$ 347,488</u>	<u>\$ 988,753</u>
	For the year ended December 31, 2024		
	Operating costs	Operating expenses	Total
Salaries and wages	\$ 559,261	\$ 290,369	\$ 849,630
Labor and health insurance expenses	48,599	21,447	70,046
Pension costs	30,418	12,654	43,072
Other personnel expenses	27,459	20,787	48,246
	<u>\$ 665,737</u>	<u>\$ 345,257</u>	<u>\$ 1,010,994</u>

- A. According to the Articles of Incorporation of the Company, a ratio of distributable profit of the current year, after covering accumulated losses, shall be distributed as employees' compensation and directors' remuneration. The ratio shall not be lower than 2% for employees' compensation (compensation for rank-and-file employees shall not be less than 1%) and shall not be higher than 2% for directors' remuneration.
- B. For the years ended December 31, 2025 and 2024, the employees' compensation was accrued at \$14,733 and \$41,293, respectively, while the directors' remuneration was accrued at \$2,191 and \$5,430, respectively. The aforementioned amounts were recognised in salary expenses and were estimated and accrued based on the earnings of current year and the percentage specified in the Articles of Incorporation of the Company. The actual amount approved at the Board of Directors' meeting for employees' compensation and directors' remuneration for 2024 was \$46,723, which was the same as the amount recognised in the 2024 financial statements. The employees' compensation was distributed in the form of cash for 2024. On March 4, 2026, the employees' compensation and directors' remuneration resolved by the Board of Directors were \$14,733 and \$2,191, respectively, and the employees' compensation will be distributed in the form of cash. Information about the appropriation of employees' compensation and directors' remuneration by the Company as resolved by the Board of Directors will be posted in the "Market Observation Post System" at the website of the Taiwan Stock Exchange.

(24) INCOME TAX

A. Income tax expense

(a) Components of income tax expense:

	For the years ended December 31,	
	2025	2024
Current income tax:		
Income tax for the year	\$ 50,624	\$ 61,214
Over provision of prior year's income tax	(96)	(2,967)
Total current tax	<u>50,528</u>	<u>58,247</u>
Deferred income tax:		
Origination and reversal of temporary differences	(40,104)	15,420
Income tax expense	<u>\$ 10,424</u>	<u>\$ 73,667</u>

(b) The income tax relating to components of other comprehensive income is as follows:

	For the years ended December 31,	
	2025	2024
Remeasurement of defined benefit obligations	<u>\$ 62</u>	<u>(\$ 107)</u>

B. Reconciliation between income tax expense and accounting profit:

	For the years ended December 31,	
	2025	2024
Income tax at statutory tax rate	\$ 8,304	\$ 87,442
Effect of items disallowed by tax	482	1,203
Effect of investment tax credits	(19,476)	(7,239)
Change in the assessment of the realisability	21,210	(4,772)
Over provision of prior year's income tax	(96)	(2,967)
Income tax expense	<u>\$ 10,424</u>	<u>\$ 73,667</u>

Note: The basis for computing the applicable tax rate are the rates applicable in the respective countries where the Group entities operate.

C. Amounts of deferred tax assets or liabilities as a result of temporary differences and loss carryforward are as follows:

For the year ended December 31, 2025				
	January 1	Recognised in profit or loss	Recognised in other comprehensive income	December 31
Deferred tax assets:				
Temporary differences:				
Unrealised loss on inventory market value decline	\$ 64,752	\$ 13,456	\$ -	\$ 78,208
Unrealised loss on components and spare parts market value decline	17,427	(117)	-	17,310
Investment loss	433,076	29,033	-	462,109
Pensions	4,722	(2,521)	(62)	2,139
Employee benefits - unused compensated absences	3,371	134	-	3,505
Impairment of assets	826	(450)	-	376
Unrealised loss on financial liabilities	245	(245)	-	-
Loss carryforward	<u>100,841</u>	<u>138</u>	<u>-</u>	<u>100,979</u>
	<u>\$ 625,260</u>	<u>\$ 39,428</u>	<u>(\$ 62)</u>	<u>\$ 664,626</u>
Deferred tax liabilities:				
Temporary differences:				
Unrealised exchange gain	(\$ 1,304)	\$ 694	\$ -	(\$ 610)
Unrealised gain on financial assets	-	(18)	-	(18)
	<u>(\$ 1,304)</u>	<u>\$ 676</u>	<u>\$ -</u>	<u>(\$ 628)</u>
	<u>\$ 623,956</u>	<u>\$ 40,104</u>	<u>(\$ 62)</u>	<u>\$ 663,998</u>

For the year ended December 31, 2024

	January 1	Recognised in profit or loss	Recognised in other comprehensive income	December 31
Deferred tax assets:				
Temporary differences:				
Unrealised loss on inventory market value decline	\$ 64,931	(\$ 179)	\$ -	\$ 64,752
Unrealised loss on components and spare parts market value decline	17,345	82	-	17,427
Investment loss	441,260	(8,184)	-	433,076
Pensions	10,903	(6,288)	107	4,722
Employee benefits - unused compensated absences	5,098	(1,727)	-	3,371
Impairment of assets	603	223	-	826
Unrealised exchange loss	3,697	(3,697)	-	-
Unrealised loss on financial liabilities	-	245	-	245
Loss carryforward	97,093	3,748	-	100,841
	<u>\$ 640,930</u>	<u>(\$ 15,777)</u>	<u>\$ 107</u>	<u>\$ 625,260</u>
Deferred tax liabilities:				
Temporary differences:				
Unrealised exchange gain	\$ -	(\$ 1,304)	\$ -	(\$ 1,304)
Unrealised gain on financial assets	(1,661)	1,661	-	-
	<u>(\$ 1,661)</u>	<u>\$ 357</u>	<u>\$ -</u>	<u>(\$ 1,304)</u>
	<u>\$ 639,269</u>	<u>(\$ 15,420)</u>	<u>\$ 107</u>	<u>\$ 623,956</u>

D. Expiration dates of unused operating loss carryforward and amounts of unrecognised deferred tax assets are as follows:

December 31, 2025				
Year incurred	Amount filed /assessed	Unused tax credits	Unrecognised deferred tax assets	Expiry year (Note)
2017~2023	\$ 1,065,533	\$ 1,060,826	\$ 536,820	2027~2033
2025	149,190	149,190	-	2035
	<u>\$ 1,214,723</u>	<u>\$ 1,210,016</u>	<u>\$ 536,820</u>	

December 31, 2024

Year incurred	Amount filed /assessed	Unused tax credits	Unrecognised deferred tax assets	Expiry year (Note)
2017~2023	\$ 1,064,068	\$ 1,021,327	\$ 349,056	2027~2033

Note: In December 2022, SciAnda (Changshu) Pharmaceuticals, Ltd., a subsidiary of the Group, obtained the qualification of High and New Tech Enterprises in mainland China. The income tax rate was reduced to 15%, and the deduction period of unused tax losses was extended to 10 years.

E. The Company's income tax returns through 2023 have been assessed and approved by the Tax Authority, and there were no disputes existing between the Company and the Authority as of March 4, 2026.

(25) EARNINGS PER SHARE ("EPS")

	For the year ended December 31, 2025		
	<u>Amount after tax</u>	<u>Weighted average number of shares outstanding (shares in thousands)</u>	<u>EPS (in dollars)</u>
<u>Basic earnings per share</u>			
Profit attributable to ordinary stockholders of the parent	\$ 136,951	790,739	\$ 0.17
<u>Diluted earnings per share</u>			
Profit attributable to ordinary stockholders of the parent	\$ 136,951	790,739	
Assumed conversion of all dilutive potential ordinary shares			
Employees' stock options	-	-	
Employees' compensation	-	1,177	
Profit attributable to ordinary stockholders of the parent plus assumed conversion of all dilutive potential ordinary shares	\$ 136,951	791,916	\$ 0.17

	For the year ended December 31, 2024		
	Amount after tax	Weighted average number of shares outstanding (shares in thousands)	EPS (in dollars)
<u>Basic earnings per share</u>			
Profit attributable to ordinary stockholders of the parent	\$ 339,350	790,739	\$ 0.43
<u>Diluted earnings per share</u>			
Profit attributable to ordinary stockholders of the parent	\$ 339,350	790,739	
Assumed conversion of all dilutive potential ordinary shares			
Employees' stock options	-	-	
Employees' compensation	-	2,132	
Profit attributable to ordinary stockholders of the parent plus assumed conversion of all dilutive potential ordinary shares	\$ 339,350	792,871	\$ 0.43

For the years ended December 31, 2025 and 2024, some abovementioned stock options issued were anti-dilutive; therefore they were not included in the diluted EPS calculation.

(26) SUPPLEMENTAL CASH FLOW INFORMATION

A. Investing activities with partial cash payments:

	For the years ended December 31,	
	2025	2024
Purchase of property, plant and equipment	\$ 84,350	\$ 161,089
Add: Beginning balance of payable on equipment (listed as "Other payables")	102,971	56,759
Less: Ending balance of payable on equipment (listed as "Other payables")	(41,946)	(102,971)
Cash paid for acquisition of property, plant and equipment	\$ 145,375	\$ 114,877
	For the years ended December 31,	
	2025	2024
Purchase of prepayments for equipment	\$ 114,943	\$ 216,543
Add: Beginning balance of payable on equipment (listed as "Other payables")	51,251	-
Less: Ending balance of payable on equipment (listed as "Other payables")	(20,280)	(51,251)
Cash paid for prepayments for equipment	\$ 145,914	\$ 165,292

B. Operating and investing activities with no cash flow effects:

	For the years ended December 31,	
	2025	2024
Inventory reclassified to prepayments	\$ 3,820	\$ 632
Property, plant and equipment reclassified to intangible assets	\$ 1,278	\$ -
Property, plant and equipment reclassified to other non-current assets	\$ 5,755	\$ -
Prepayments for equipment reclassified to property, plant and equipment	\$ 69,705	\$ 245,852
Prepayments for equipment reclassified to other non-current assets	\$ 51,732	\$ -

(27) CHANGES IN LIABILITIES FROM FINANCING ACTIVITIES

For the year ended December 31, 2025	Short-term borrowings	Lease liabilities	Guarantee deposits received	Liabilities from financing activities-gross
At January 1, 2025	\$ 35,563	\$ 639,980	\$ 3,992	\$ 679,535
Changes in cash flow from financing activities	91,333	(15,983)	(890)	74,460
Impact of changes in foreign exchange rate	3,528	-	(56)	3,472
Changes in other non-cash items	-	8,241	-	8,241
At December 31, 2025	<u>\$ 130,424</u>	<u>\$ 632,238</u>	<u>\$ 3,046</u>	<u>\$ 765,708</u>
For the year ended December 31, 2024	Short-term borrowings	Lease liabilities	Guarantee deposits received	Liabilities from financing activities-gross
At January 1, 2024	\$ 32,137	\$ 587,787	\$ 1,297	\$ 621,221
Changes in cash flow from financing activities	2,170	(12,472)	2,637	(7,665)
Impact of changes in foreign exchange rate	1,256	-	58	1,314
Changes in other non-cash items	-	64,665	-	64,665
At December 31, 2024	<u>\$ 35,563</u>	<u>\$ 639,980</u>	<u>\$ 3,992</u>	<u>\$ 679,535</u>

7. RELATED PARTY TRANSACTIONS

(1) Parent and ultimate controlling party

The ultimate parent and ultimate controlling party of the Company is Uni-President Enterprises Corp.

(2) Names of related parties and relationship

Names of related parties	Relationship with the Company
Uni-President Enterprises Corp.	Ultimate parent company
President Securities Corp.	Associate of ultimate parent company
President Transnet Corp.	Associate of ultimate parent company
President Tokyo Corp.	Associate of ultimate parent company
Mech-President Corp.	Associate of ultimate parent company
President Chain Store Corp.	Associate of ultimate parent company
President Chain Store Tokyo Marketing Corp.	Associate of ultimate parent company
President Information Corp.	Associate of ultimate parent company
Duskin Serve Taiwan Co., Ltd.	Associate of ultimate parent company
Uni-President Enterprises (China) Investment Corp.	Associate of ultimate parent company
Uni-President Shanghai Pearly Century Co., Ltd.	Associate of ultimate parent company

(3) Significant transactions and balances with related parties

A. Property transactions

	For the years ended December 31,	
	2025	2024
Acquisition of property, plant and equipment		
— Ultimate parent company	\$ 74	\$ 2
— Associate of ultimate parent company	286	1,017
	<u>\$ 360</u>	<u>\$ 1,019</u>

B. Other expenses

	For the years ended December 31,	
	2025	2024
Management service fees:		
— Ultimate parent company	\$ 2,235	\$ 1,963
— Associate of ultimate parent company	2,965	3,038
	<u>\$ 5,200</u>	<u>\$ 5,001</u>
Rent expenses		
— Associate of ultimate parent company	<u>\$ 3,552</u>	<u>\$ 3,688</u>

(4) Key management compensation

	For the years ended December 31,	
	2025	2024
Salaries and other short-term employee benefits	\$ 44,332	\$ 53,930
Post-employment benefits	482	555
Termination benefits	1,600	1,596
	<u>\$ 46,414</u>	<u>\$ 56,081</u>

8. PLEDGED ASSETS

Details of the Group's assets pledged as collateral are as follows:

Assets	December 31, 2025	December 31, 2024	Purpose of collateral
Pledged time deposits (Note)	<u>\$ 29,270</u>	<u>\$ 30,940</u>	Performance guarantee, customs duty and guarantee for credit

Note: Listed as "Other financial assets - non-current".

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT COMMITMENTS

(1) As of December 31, 2025 and 2024, the Group's remaining balance due for construction in progress and prepayments for equipment was \$15,218 and \$43,512, respectively.

(2) The amounts of endorsements and guarantees for subsidiaries were as follows:

	Nature	December 31, 2025	December 31, 2024
SciAnda (Changshu) Pharmaceuticals, Ltd.	Guarantee for financing amount	<u>\$ -</u>	<u>\$ 179,661</u>

As of December 31, 2025 and 2024, the actual amount drawn down for endorsements and guarantees to subsidiaries was \$—.

10. SIGNIFICANT DISASTER LOSS

None.

11. SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

None.

12. OTHERS

(1) Capital management

The Group's objectives on managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders, to maintain an optimal capital structure, to reduce the cost of capital and to maintain an adequate capital structure to enable the expansion and enhancement of equipment. In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return of capital to shareholders, and issue new shares or sell assets to reduce debts.

(2) Financial instruments

A. Financial instruments

For details of the Group's financial instruments by category, refer to Note 6.

B. Risk management policies

- (a) The Group's activities expose it to a variety of financial risks: market risk (including foreign exchange risk, price risk and interest rate risk), credit risk and liquidity risk.
- (b) The Group's treasury identifies, evaluates and hedges financial risks closely with the Group's operating units. The Board provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as use of derivative financial instruments and investment of excess liquidity.
- (c) Information about derivative financial instruments that are used to hedge financial risk are provided in Note 6(2), "Financial assets and liabilities at fair value through profit or loss".

C. Significant financial risks and degrees of financial risks

(a) Market risk

I. Foreign exchange rate risk

- (i) The Group operates internationally and is exposed to foreign exchange risk arising from the transactions of the Company and its subsidiaries used in various functional currency, primarily with respect to USD. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities.
- (ii) To manage their foreign exchange risk arising from future commercial transactions and recognised assets and liabilities, entities in the Group are required to hedge their foreign exchange risk exposure using forward foreign exchange contracts. However, the Group does not adopt hedging accounting. Details of financial assets or liabilities at fair value through profit or loss are provided in Note 6(2), "Financial assets and liabilities at fair value through profit or loss".
- (iii) The Group's businesses involve some non-functional currency operations (the Company's and certain subsidiaries' functional currency: NTD; other subsidiaries' functional currency: CNY). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations is as follows:

				December 31, 2025			
				Foreign currency			Book value
				<u>amount (in thousands)</u>	<u>Exchange rate</u>	<u>(NTD)</u>	
(Foreign currency: functional currency)							
<u>Financial assets</u>							
<u>Monetary items</u>							
USD:NTD	\$	18,222		31.43	\$	572,717	
<u>Financial liabilities</u>							
<u>Monetary items</u>							
GBP:NTD		99		42.33		4,191	
USD:NTD		41		31.43		1,289	
EUR:NTD		53		36.90		1,956	
				December 31, 2024			
				Foreign currency			Book value
				<u>amount (in thousands)</u>	<u>Exchange rate</u>	<u>(NTD)</u>	
(Foreign currency: functional currency)							
<u>Financial assets</u>							
<u>Monetary items</u>							
USD:NTD	\$	19,110		32.79	\$	626,617	
CNY:NTD		8,827		4.492		39,651	
<u>Financial liabilities</u>							
<u>Monetary items</u>							
USD:NTD		712		32.79		23,346	
GBP:NTD		173		41.19		7,126	
EUR:NTD		48		34.14		1,639	
JPY:NTD		5,264		0.210		1,105	

- (iv) As of December 31, 2025 and 2024, if the NTD:USD exchange rate appreciates/depreciates by 5% with all other factors remaining constant, the Group's net profit after tax for the years ended December 31, 2025 and 2024 would increase/decrease by \$22,857 and \$24,130, respectively. If the exchange rate of NTD to other currencies had appreciated/depreciated by 5% with all other factors remaining constant, the effect on the Group's net profit after tax for the years ended December 31, 2025 and 2024 is immaterial.
- (v) Total exchange (loss) gain including realised and unrealised arising from significant foreign exchange variation on the monetary items held by the Group for the years ended December 31, 2025 and 2024 amounted to (\$24,201) and \$48,519, respectively.

II. Price risk

- (i) The Group's equity securities, which are exposed to price risk, are the held financial assets and liabilities at fair value through profit or loss and financial assets at fair value through other comprehensive income. To manage its price risk arising from investments in equity securities, the Group diversifies its portfolio and set stop-loss amounts for these instruments. The Group expects no significant market risk.
- (ii) The Group's investments in equity securities comprise equity securities issued by the domestic and foreign companies. The prices of equity securities would change due to the change of the future value of investee companies. If the prices of these equity securities had increased/decreased by 5% with all other variables held constant, other components of equity would have increased/decreased by \$68,387 and \$3,507 for the years ended December 31, 2025 and 2024, respectively, as a result of other comprehensive income on equity investments classified as at fair value through other comprehensive income.

III. Cash flow and fair value interest rate risk

- (i) The Group's main interest rate risk arises from short-term borrowings with variable rates and exposes the Group to cash flow interest rate risk. During the years ended December 31, 2025 and 2024, the Group's borrowings at variable rate were denominated in CNY.
- (ii) The Group's borrowings are measured at amortised cost. The borrowings are periodically contractually repriced and to that extent are also exposed to the risk of future changes in market interest rates.
- (iii) If the borrowing interest rates had increased/decreased by 10% with all other variables held constant, the effect on post-tax profit for the years ended December 31, 2025 and 2024 is immaterial.

(b) Credit risk

- I. Credit risk refers to the risk of financial loss to the Group arising from default by the clients or counterparties of financial instruments on the contract obligations. The main factor is that counterparties could not repay in full the accounts receivable based on the agreed terms.
- II. The Group manages its credit risk taking into consideration the entire group's concern. For banks and financial institutions, only independently rated parties with a minimum rating of 'A' are accepted. According to the Group's credit policy, each local entity in the Group is responsible for managing and analysing the credit risk for each of their new clients before standard payment and delivery terms and conditions are offered. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the Board of Directors. The utilisation of credit limits is regularly monitored.

- III. The Group adopts the following assumption under IFRS 9: If the contract payments were past due over 30 days based on the terms, there has been a significant increase in credit risk on that instrument since initial recognition.
- IV. The Group manages its credit risk, whereby if the contract payments are past due over 180 days based on the terms, there has been impairment.
- V. The Group classifies customers' accounts receivable in accordance with the credit rating of the customer and credit risk on trade. The Group applies the simplified approach using the provision matrix to estimate expected credit loss, and use the forecastability to adjust historical and timely information to assess the default possibility of accounts receivable. Movements in relation to the Group applying the simplified approach to provide loss allowance for accounts receivable are as follows:

	For the years ended December 31,	
	2025	2024
At January 1	\$ 1,904	\$ 231
Expected credit (gain) loss	(41)	1,668
Impact of foreign exchange rate	-	5
At December 31	<u>\$ 1,863</u>	<u>\$ 1,904</u>

(c) Liquidity risk

- I. Cash flow forecasting is performed by the Group's treasury department which monitors rolling forecasts of the Group's liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities at all times so that the Group does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities.
- II. The Group has undrawn borrowing facilities amounting to \$5,104,605 and \$4,970,318 as of December 31, 2025 and 2024, respectively.
- III. The following table comprises the Group's non-derivative financial liabilities and derivative financial liabilities with gross-amount settlement that are grouped by their maturity. Non-derivative financial liabilities are analysed from the balance sheet date to the contract maturity date, and derivative financial liabilities are analysed from the balance sheet date to the expected maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

<u>December 31, 2025</u>	<u>Less than 1 year</u>	<u>Between 1 and 2 years</u>	<u>Between 2 and 5 years</u>	<u>More than 5 years</u>
Non-derivative financial liabilities:				
Short-term borrowings	\$ 132,112	\$ -	\$ -	\$ -
Notes payable	12	-	-	-
Accounts payable	62,515	-	-	-
Other payables	363,581	-	-	-
Lease liabilities	23,622	19,098	55,194	699,131
Guarantee deposits received	-	3,046	-	-
	<u>Less than 1 year</u>	<u>Between 1 and 2 years</u>	<u>Between 2 and 5 years</u>	<u>More than 5 years</u>
<u>December 31, 2024</u>				
Non-derivative financial liabilities:				
Short-term borrowings	\$ 36,174	\$ -	\$ -	\$ -
Notes payable	1,211	-	-	-
Accounts payable	80,959	-	-	-
Other payables	498,191	-	-	-
Lease liabilities	19,764	19,422	55,195	717,529
Guarantee deposits received	-	3,992	-	-
Derivative financial liabilities:				
Forward exchange contracts	1,225	-	-	-

(3) Fair value information

A. The different levels that the inputs to valuation techniques are used to measure fair value of financial and non-financial instruments have been defined as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. A market is regarded as active where a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. The fair value of the Group's investment in private placement of listed stocks and foreign exchange contracts is included in Level 2.

Level 3: Unobservable inputs for the asset or liability. The fair value of the Group's investment in equity investment without active market is included in Level 3.

B. Financial instruments not measured at fair value

The carrying amounts of cash and cash equivalents, contract assets, accounts receivable, other receivables, guarantee deposits paid, other financial assets - non-current, short-term borrowings, notes payable, accounts payable, other payables and guarantee deposits received are approximate to their fair values.

C. The related information on financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets and liabilities are as follows:

<u>December 31, 2025</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets:				
<u>Recurring fair value measurements</u>				
Financial assets at fair value through profit or loss				
Derivative instruments	\$ -	\$ 90	\$ -	\$ 90
Financial assets at fair value through other comprehensive income				
Equity securities	\$ -	\$ 1,308,490	\$ 59,248	\$ 1,367,738
<u>December 31, 2024</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets:				
<u>Recurring fair value measurements</u>				
Financial assets at fair value through other comprehensive income				
Equity securities	\$ -	\$ -	\$ 70,134	\$ 70,134
Liabilities:				
<u>Recurring fair value measurements</u>				
Financial liabilities at fair value through profit or loss				
Derivative instruments	\$ -	\$ 1,225	\$ -	\$ 1,225

D. The methods and assumptions the Group used to measure fair value are as follows:

- (a) The fair value of other financial instruments is measured by using valuation techniques or by reference to counterparty quotes. The fair value of financial instruments measured by using valuation techniques can be referred to current fair value of instruments with similar terms and characteristics in substance, discounted cash flow method or other valuation methods, including calculated by applying model using market information available at the consolidated balance sheet date.
- (b) When assessing non-standard and low-complexity financial instruments, for example, debt instruments without active market, interest rate swap contracts, foreign exchange swap contracts and options, the Group adopts valuation technique that is widely used by market participants. The inputs used in the valuation method to measure these financial instruments are normally observable in the market.

(c) Forward foreign exchange contracts are usually valued based on the current forward exchange rate.

E. For the years ended December 31, 2025 and 2024, there was no transfer between Level 1 and Level 2.

F. The following chart is the movement of Level 3 for the years ended December 31, 2025 and 2024:

	For the years ended December 31,	
	2025	2024
	Equity instrument	Equity instrument
At January 1	\$ 70,134	\$ 69,973
(Loss) gain recognised in other comprehensive income	(10,886)	161
At December 31	<u>\$ 59,248</u>	<u>\$ 70,134</u>

For the years ended December 31, 2025 and 2024, there was no transfer in (out) of Level 3.

G. The Group's valuation procedures for fair value measurements is categorised within Level 3, which is to verify independent fair value of financial instruments. Such assessment is to ensure the valuation results are reasonable by applying independent information to make results close to current market conditions, confirming the resource of information is independent, reliable and in line with other resources and represented as the exercisable price, and frequently assess to make any other necessary adjustments to the fair value.

H. The following is the qualitative information of significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement:

	Fair value at December 31, 2025	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship of inputs to fair value
Non-derivative equity					
Unlisted shares	\$ 59,248	Net asset value	Discount for lack of	50%	The higher the discount for lack of marketability, the lower the fair value

	Fair value at December 31, 2024	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship of inputs to fair value
Non-derivative equity					
Unlisted shares	\$ 70,134	Net asset value	Discount for lack of	50%	The higher the discount for lack of marketability, the lower the fair value

I. The Group has carefully assessed the valuation models and assumptions used to measure fair value. However, use of different valuation models or assumptions may result in different measurement. If the discount for lack of marketability increased or decreased by 1% for Level 3, the effect on other comprehensive income for the years ended December 31, 2025 and 2024 is immaterial.

13. SUPPLEMENTARY DISCLOSURES

According to the current regulatory requirements, the Group is only required to disclose the information for the year ended December 31, 2025.

(1) Significant transactions information

- A. Loans to others: None.
- B. Provision of endorsements and guarantees to others: Refer to table 1.
- C. Holding of significant marketable securities at the end of the period (not including subsidiaries, associates and joint ventures): Refer to table 2.
- D. Purchases or sales of goods from or to related parties reaching \$100 million or 20% of paid-in capital or more: Refer to table 3.
- E. Receivables from related parties reaching \$100 million or 20% of paid-in capital or more: None.
- F. Significant inter-company transactions during the reporting period: Refer to table 4.

(2) Information on investees

Names, locations and other information of investee companies (not including investees in Mainland China): Refer to table 5.

(3) Information on investments in Mainland China

- A. Basic information: Refer to table 6.
- B. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: Refer to table 1 and table 4.

14. SEGMENT INFORMATION

(1) General information

The management of the Group has identified the operating segments based on how the Company's Chief Operating Decision-Maker regularly reviews information in order to make decisions. The

Chief Operating Decision-Maker manages the Group’s business from geographical and functional perspectives. Geographically, the Group focuses on its sales business in the U.S., Europe and Asia. In addition, the Group categorised its business units into manufacture, sales, research and development and investment management functions, and combines its segments that meet the disclosure threshold as “Others”.

(2) Measurement of segment information

The chief operating decision-maker evaluates the performance of operating segments based on pre-tax income excluding non-recurring income. For details of operating segments’ accounting policies, refer to Note 4.

(3) Segment information

The segment information provided to the Chief Operating Decision-Maker for the reportable segments is as follows:

	For the year ended December 31, 2025			
	ScinoPharm	SciAnda (Changshu)		
	Taiwan, Ltd.	Pharmaceuticals Ltd.	Others	Total
Segment revenue	\$ 3,108,908	\$ 389,670	\$ 15,888	\$ 3,514,466
Revenue from internal customers	15	336,078	14,951	351,044
Revenue from external customers	3,108,893	53,592	937	3,163,422
– API Income	2,674,121	41,767	-	2,715,888
– Injection Product Income	174,554	-	-	174,554
– Technical Service Income	227,476	11,825	937	240,238
– Other Operating Income	32,742	-	-	32,742
Interest income	53,004	238	134	53,376
Depreciation and amortisation	398,031	117,953	744	516,728
Interest expense	7,282	2,585	-	9,867
Income (loss) from segment before income tax	292,490	(141,405)	693	151,778
Segment assets	10,240,359	1,677,762	26,610	11,944,731
Acquisition of non-current assets	178,448	27,490	40	205,978
Segment liabilities	1,123,422	214,014	1,262	1,338,698

	For the year ended December 31, 2024			
	ScinoPharm Taiwan, Ltd.	SciAnda (Changshu) Pharmaceuticals Ltd.	Others	Total
Segment revenue	\$ 3,139,056	\$ 679,162	\$ 19,952	\$ 3,838,170
Revenue from internal customers	9,594	404,119	18,173	431,886
Revenue from external customers	3,129,462	275,043	1,779	3,406,284
– API Income	2,751,460	270,035	52	3,021,547
– Injection Product Income	80,070	-	-	80,070
– Technical Service Income	253,118	5,008	1,727	259,853
– Other Operating Income	44,814	-	-	44,814
Interest income	60,930	403	188	61,521
Depreciation and amortisation	375,496	111,702	1,083	488,281
Interest expense	7,292	791	-	8,083
Income from segment before income tax	372,012	31,812	1,789	405,613
Segment assets	10,214,243	1,816,848	29,543	12,060,634
Acquisition of non-current assets	216,672	180,435	43	397,150
Segment liabilities	1,244,515	208,521	4,901	1,457,937

(4) Reconciliation for segment

A. The sales between segments were at arms' length. The external revenues reported to the Chief Operating Decision-Maker adopt the same measurement basis for revenues in the statement of comprehensive income. The reconciliations of pre-tax income between reportable segments and continuing operations were as follows:

	For the years ended December 31,	
	2025	2024
Reportable segments profit before income tax	\$ 151,085	\$ 403,824
Other segments income before income tax	693	1,789
Internal segments transaction elimination	(4,403)	7,404
Profit before income tax	<u>\$ 147,375</u>	<u>\$ 413,017</u>

B. The amount of total assets provided to the Chief Operating Decision-Maker adopts the same measurement for assets in the Group's financial statements. A reconciliation of assets of reportable segments and total assets is as follows:

	December 31, 2025	December 31, 2024
Assets of reportable segments	\$ 11,918,121	\$ 12,031,091
Assets of other operating segments	26,610	29,543
Internal segment transaction elimination	(87,006)	(117,896)
Total assets	<u>\$ 11,857,725</u>	<u>\$ 11,942,738</u>

C. The amount of total liabilities provided to the Chief Operating Decision-Maker adopts the same measurement for liabilities in the Group's financial statements. A reconciliation of liabilities of reportable segments and total liabilities is as follows:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Liabilities of reportable segments	\$ 1,337,436	\$ 1,453,036
Liabilities of other operating segments	1,262	4,901
Internal segment transaction elimination	(5,710)	(41,003)
Total liabilities	<u>\$ 1,332,988</u>	<u>\$ 1,416,934</u>

(5) Information on product and service

The Group is engaged in the research and development and manufacture of API, as well as the provision of related consulting and technical services. The reconciliations of total segment and operating revenue were as follows:

	<u>For the years ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Revenue from sales of API products	\$ 2,715,888	\$ 3,021,547
Revenue from technical services	240,238	259,853
Revenue from sales of injection products	174,554	80,070
Others	32,742	44,814
Total operating revenue	<u>\$ 3,163,422</u>	<u>\$ 3,406,284</u>

(6) Geographical information

Geographical information for the years ended December 31, 2025 and 2024 is as follows:

	<u>For the year ended December 31, 2025</u>		<u>For the year ended December 31, 2024</u>	
	<u>Revenue</u>	<u>Non-current assets</u>	<u>Revenue</u>	<u>Non-current assets</u>
Asia	\$ 950,463	\$ 1,239,214	\$ 1,415,312	\$ 1,333,722
Europe	479,487	-	675,059	-
India	438,401	-	529,294	-
USA	855,948	-	403,664	-
Taiwan	400,925	3,063,134	346,884	3,272,225
Others	38,198	-	36,071	-
	<u>\$ 3,163,422</u>	<u>\$ 4,302,348</u>	<u>\$ 3,406,284</u>	<u>\$ 4,605,947</u>

(7) Major customer information

Major customers (individually over 10% of consolidated operating revenue) information of the Group for the years ended December 31, 2025 and 2024 is as follows:

	<u>For the year ended December 31, 2025</u>		<u>For the year ended December 31, 2024</u>	
	<u>Revenue</u>	<u>Segment</u>	<u>Revenue</u>	<u>Segment</u>
A	\$ 327,412	ScinoPharm Taiwan, Ltd.	\$ 191,586	ScinoPharm Taiwan, Ltd.
B	316,670	"	386,698	"
	<u>\$ 644,082</u>		<u>\$ 578,284</u>	

ScinoPharm Taiwan, Ltd. and Subsidiaries
Provision of endorsements and guarantees to others
For the year ended December 31, 2025

Table 1

Expressed in thousands of NTD

Number	Endorser/ guarantor	Party being endorsed/guaranteed Company name	Relationship with the endorser/ guarantor (Note 1)	Limit on endorsements/ guarantees provided for a single party (Note 2)	Maximum outstanding endorsement/ guarantee amount during the year	Outstanding endorsement/ guarantee amount at December 31, 2025	Actual amount drawn down	Amount of endorsements/ guarantees secured with collateral	Ratio of accumulated endorsement/ guarantee amount to net asset value of the endorser/ guarantor company	Ceiling on total amount of endorsements/ guarantees provided (Note 2)	Provision of endorsements/ guarantees by parent company to subsidiary	Provision of endorsements/ guarantees by parent subsidiary to parent company	Provision of endorsements/ guarantees to the party in Mainland China	Footnote
0	ScinoPharm Taiwan, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	1	\$ 10,524,737	\$ 180,465	\$ -	\$ -	\$ -	-	\$ 10,524,737	Y	N	Y	—

Note 1: The following code represents the relationship with the Company:

1.A company in which the Company directly and indirectly holds 50% of the voting shares.

Note 2: 1.The limit of total amount of endorsement is 50% of the Company's net worth, for 100% directly or indirectly owned subsidiaries, the maximum amount is 100% of its net worth.

The limit of total amount of the Group's endorsement and guarantee is 100% of the Group's net worth.

2.For any endorsement or guarantee provided by the Company due to business dealings, the amount of endorsement or guarantees shall be limited to the business dealing amount of the most recent year or the current year.

The business dealing amount is product purchase or sale amount between the entities, whichever is higher.

Note 3: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the consolidated financial statements (CNY:NTD 1:4.498).

ScinoPharm Taiwan, Ltd. and Subsidiaries

Holding of significant marketable securities at the end of the period (not including subsidiaries, associates and joint ventures)

December 31, 2025

Table 2

Expressed in thousands of NTD

Securities held by	Marketable securities	Relationship with the securities issuer	General ledger account	As of December 31, 2025			Fair value	Footnote
				Number of shares	Book value	Ownership (%)		
ScinoPharm Taiwan, Ltd.	Stocks:							
	Handa Pharmaceuticals, Inc.	The Company is a director of Handa Pharmaceuticals, Inc.	Financial assets at fair value through other comprehensive income - non-current	17,000,000	\$ 1,308,490	10.00%	\$ 1,308,490	—
	Tanvex Biologics, Inc.	The Company is a director of Tanvex Biologics, Inc.	Financial assets at fair value through other comprehensive income - non-current	28,800,000	59,248	16.84%	59,248	—

ScinoPharm Taiwan, Ltd. and Subsidiaries

Purchases or sales of goods from or to related parties reaching \$100 million or 20% of paid-in capital or more

For the year ended December 31, 2025

Table 3

Expressed in thousands of NTD

Purchaser/seller	Counterparty	Relationship with the counterparty	Transaction				Differences in transaction terms compared to third party transactions		Notes/accounts receivable (payable)		Footnote
			Purchases (sales)	Amount	Percentage of total purchases (sales)	Credit term	Unit price	Credit term	Balance	Percentage of total notes/accounts receivable (payable)	
ScinoPharm Taiwan, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	Subsidiary	Purchases	\$ 339,649	42%	Closes its accounts 90 days from the end of each month	\$ -	-	(\$ 1,229)	(2%)	-
SciAnda (Changshu) Pharmaceuticals, Ltd.	ScinoPharm Taiwan, Ltd.	The Company	(Sales)	(339,649)	(90%)	Closes its accounts 90 days from the end of each month	-	-	1,229	4%	-

ScinoPharm Taiwan, Ltd. and Subsidiaries

Significant inter-company transactions during the reporting period

For the year ended December 31, 2025

Table 4

Expressed in thousands of NTD

Number (Note 2)	Company name	Counterparty	Relationship (Note 3)	Transactions			Percentage of consolidated total operating revenues or total assets (Note 4)
				General ledger account	Amount	Transaction terms	
0	ScinoPharm Taiwan, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	1	Purchases	\$ 339,649	Closes its accounts 90 days from the end of each month	11%

Note 1: Significant inter-company transactions during the reporting periods are not disclosed since these were corresponding transactions. Only transactions over NT\$10 million are material.

Note 2: The numbers filled in for the transaction company in respect of inter-company transactions are as follows:

(1) Parent company is '0'.

(2) The subsidiaries are numbered in order starting from '1'.

Note 3: Relationship between transaction company and counterparty is classified into the following three categories:

(1) Parent company to subsidiary.

(2) Subsidiary to parent company.

(3) Subsidiary to subsidiary.

Note 4: Regarding percentage of transaction amount to consolidated total operating revenues or total assets, it is computed based on period-end balance of transaction to consolidated total assets for balance sheet accounts and based on accumulated transaction amount for the period to consolidated total operating revenues for income statement accounts.

Note 5: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the consolidated financial statements (CNY:NTD 1:4.498 ; USD:NTD 1:31.43).

ScinoPharm Taiwan, Ltd. and Subsidiaries

Names, locations and other information of investee companies (not including investees in Mainland China)

For the year ended December 31, 2025

Table 5

Expressed in thousands of NTD

Investor	Investee	Location	Main business activities	Initial investment amount		Shares held as at December 31, 2025			Net profit of the investee for the year ended December 31, 2025	Investment income recognised by the Company		Footnote
				Balance as at December 31, 2025	Balance as at December 31, 2024	Number of shares	Ownership (%)	Book value		for the year ended December 31, 2025	for the year ended December 31, 2025	
ScinoPharm Taiwan, Ltd.	SPT International, Ltd.	Tortola, British Virgin Islands	Professional investment	\$ 3,614,585	\$ 3,614,585	118,524,644	100%	\$ 1,407,551	(\$ 140,790)	(\$ 145,193)	Subsidiary	
	ScinoPharm Singapore Pte Ltd.	Singapore	Professional investment	-	-	2	100%	249	29	29	Subsidiary	

ScinoPharm Taiwan, Ltd. and Subsidiaries

Information on investments in Mainland China – Basic information

For the year ended December 31, 2025

Table 6

Expressed in thousands of NTD

Investee in Mainland China	Main business activities	Paid-in capital	Investment method	Accumulated amount of remittance from Taiwan to Mainland China as of January 1, 2025	Amount remitted from Taiwan to Mainland China/ Amount remitted back to Taiwan for the year ended December 31, 2025		Accumulated amount of remittance from Taiwan to Mainland China as of December 31, 2025	Net income of investee for the year ended December 31, 2025	Ownership held by the Company (direct or indirect)	Investment income recognised by the Company for the year ended December 31, 2025	Book value of investments in Mainland China as of December 31, 2025	Accumulated amount of investment income remitted back to Taiwan as of December 31, 2025	Footnote
					Remitted to Mainland China	Remitted back to Taiwan							
SciAnda (Changshu) Pharmaceuticals, Ltd.	Research, development, and manufacture of API and new drugs, sales of self-produced products, etc.	\$ 3,661,595	(Note 1)	\$ 3,652,933	\$ -	\$ -	\$ 3,652,933	(\$ 141,405)	100%	(\$ 141,405)	\$ 1,463,747	\$ -	Subsidiary (Note 2)
SciAnda Shanghai Biochemical Technology, Ltd.	Import, export and sales of API and intermediates, etc.	37,716	(Note 1)	37,716	-	-	37,716	877	100%	877	22,099	-	Subsidiary (Note 2)
<u>Company name</u>	<u>as of December 31, 2025</u>	<u>Investment amount approved by the Investment Commission of the Ministry of Economic Affairs (MOEA)</u>	<u>Ceiling on investments in Mainland China imposed by the Investment Commission of MOEA (Note 3)</u>										
ScinoPharm Taiwan, Ltd.	\$ 3,729,123	\$ 3,729,123	\$ 6,314,842										

Note 1: Indirect investment in Mainland China through a company set up in a third region, SPT International, Ltd.

Note 2: The investment income recognised by the Company for the year ended December 31, 2025 was based on audited financial statements of investee companies as of and for the year ended December 31, 2025.

Note 3: The ceiling amount is 60% of the higher of net worth or consolidated net worth.

Note 4: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the financial statements (USD:NTD 1:31.43).